Ustekinumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Ustekinumab comprises 325 peer-reviewed publications across 15 journals, 63 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Crohn Disease, Psoriasis, Colitis, Ulcerative, and Alzheimer Disease. Most recent publication: Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability., J Allergy Clin Immunol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials.
    Strober B, Boehncke WH, Krueger JG, et al. · Dermatol Ther (Heidelb) · 2025
    PubMed: PMID 41060492 · NCT03370133 (BE VIVID) · Psoriasis
  2. Efficacy and safety of ustekinumab in Behçet disease: Results from the prospective phase 2 STELABEC trial.
    London J, Régent A, Dion J, et al. · J Am Acad Dermatol · 2022
    PubMed: PMID 34864108 · NCT02648581 (STELABEC) · Uveitis
  3. Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability.
    Krueger JG, Cutcutache I, Lebwohl M, et al. · J Allergy Clin Immunol · 2026
    PubMed: PMID 41580158 · NCT03370133 (BE VIVID) · Psoriasis
  4. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
    Gordon KB, Langley RG, Warren RB, et al. · JAMA Dermatol · 2022
    PubMed: PMID 35544084 · NCT03370133 (BE VIVID) · Psoriasis
  5. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
    Gordon KB, Langley RG, Warren RB, et al. · Br J Dermatol · 2024
    PubMed: PMID 37950894 · NCT03370133 (BE VIVID) · Psoriasis
  6. Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years.
    Gisondi P, Elewski B, Pinter A, et al. · J Dermatolog Treat · 2026
    PubMed: PMID 41800601 · NCT03370133 (BE VIVID) · Psoriasis
  7. Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study.
    Cleynen I, Van Moerkercke W, Billiet T, et al. · Ann Intern Med · 2016
    PubMed: PMID 26641955 · NCT03629379 (STRAUSS) · Psoriasis
  8. Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT.
    Armstrong A, Papp KA, Lebwohl M, et al. · Dermatol Ther (Heidelb) · 2026
    PubMed: PMID 41359217 · NCT03370133 (BE VIVID) · Psoriasis

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT00267969
PHOENIX1
PsoriasisPsoriasis Area-and-severity Index (PASI) 75% Improvement From Baseline at Week 12.
Week 12
Placebo8 Participants
Ustekinumab 45 mg171 Participants
Ustekinumab 90 mg170 Participants
NCT00307437PsoriasisNumber of Participants With Psoriasis Area and Severity Index (PASI) Score of 75 Percent or Above at Week 12
Week 0 to Week 12
Group I: Placebo15 Participants
Group II: Ustekinumab 45 mg273 Participants
Group III: Ustekinumab 90 mg311 Participants
NCT00723528PsoriasisPercentage of Participants With Greater Than or Equal to 75 Percent (%) Improvement in Psoriasis Area and Severity Index (PASI) Score
Week 12
Placebo (CP)6.5 Percentage of participants
Ustekinumab 45 mg (CP)59.4 Percentage of participants
Ustekinumab 90 mg (CP)67.7 Percentage of participants
NCT00747344PsoriasisThe Number of Patients Who Achieved at Least a 75% Improvement in PASI (Psoriasis Area and Severity Index) at Week 12
Week 12
Placebo3 Participants
Ustekinumab 45 mg41 Participants
NCT01008995PsoriasisThe Number of Patients Who Achieved at Least a 75% Improvement in PASI (Psoriasis Area and Severity Index) From Baseline at Week 12.
Baseline (Week 0) to Week 12
Placebo (CP)18 Participants
Ustekinumab 45 mg (CP)132 Participants
NCT01009086PsoriasisPercentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24.
Week 24
All Ustekinumab Combined46.0 Percentage of participants
Placebo22.8 Percentage of participants
Ustekinumab 45 mg42.4 Percentage of participants
Ustekinumab 90 mg49.5 Percentage of participants
NCT01077362PsoriasisPercentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24.
Week 24
All Ustekinumab Combined43.8 Percentage of participants
Placebo20.2 Percentage of participants
Ustekinumab 45 mg43.7 Percentage of participants
Ustekinumab 90 mg43.8 Percentage of participants
NCT01090427PsoriasisThe Percentage of Participants Achieving a Physician's Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 12
Week 12
Placebo5.4 Percentage of Participants
Ustekinumab Half-Standard Dosage67.6 Percentage of Participants
Ustekinumab Standard Dosage69.4 Percentage of Participants
NCT01369329Crohn DiseaseNumber of Participants With Clinical Response at Week 6
Baseline and Week 6
Placebo53 participants
Ustekinumab 130 Milligram (mg)84 participants
Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg)84 participants
NCT01369342Crohn DiseaseNumber of Participants With Clinical Response at Week 6
Week 6
Placebo60 participants
Ustekinumab 130 mg108 participants
Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg)116 participants
NCT01369355Crohn DiseaseNumber of Participants With Clinical Remission at Week 44
Week 44
Placebo Subcutaneously (SC)47 participants
Ustekinumab 90 mg SC q8w68 participants
Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w)63 participants
NCT01550744
PSTELLAR
PsoriasisThe Number of Visits at Which Participants Achieved a Static Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1)
Up to 24 weeks (Week 88 up to Week 112 [total 7 visits])
Group 1: Ustekinumab q12w Maintenance Regimen (MR)4.5 number of visits (±3.07 95% Confidence Interval)
Group 2: Ustekinumab Subject-tailored Fixed-interval MR4.1 number of visits (±2.93 95% Confidence Interval)
NCT01708603
AMAGINE-2
PsoriasisPercentage of Participants With Psoriasis Area Severity Index (PASI) 100 at Week 12
12 Weeks
Brodalumab 140mg157 Participants
Brodalumab 210mg272 Participants
Placebo2 Participants
Ustekinumab65 Participants
NCT01708603
AMAGINE-2
PsoriasisPercentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12
12 weeks
140 mg Brodalumab406 Participants
210 mg Brodalumab528 Participants
Placebo25 Participants
Ustekinumab210 Participants
NCT01708603
AMAGINE-2
PsoriasisPercentage of Participants With Static Physician Global Assessment (sPGA) Score Success (Score of 0 or 1) at Week 12
12 weeks
140 mg Brodalumab354 Participants
210 mg Brodalumab481 Participants
Placebo12 Participants
Ustekinumab183 Participants
NCT01708629
AMAGINE-3
PsoriasisPercentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12
12 weeks
140 mg Brodalumab435 Participants
210 mg Brodalumab531 Participants
Placebo19 Participants
Ustekinumab217 Participants
NCT01708629
AMAGINE-3
PsoriasisPercentage of Participants With Static Physician Global Assessment (sPGA) Success Score (Score of 0 or 1) at Week 12 - Comparison to Placebo
12 weeks
140 mg Brodalumab377 Participants
210 mg Brodalumab497 Participants
Placebo13 Participants
NCT02074982DermatitisPercentage of Participants With Moderate to Severe Plaque Psoriasis Who Achieved Psoriasis Area and Severity Index (PASI) 90 at Week 16
Week 16
AIN457 300 mg79.0 Percentage of Participants
Ustekinumab57.3 Percentage of Participants
NCT02203032
NAVIGATE
PsoriasisNumber of Visits at Which Participants Achieved an Investigator's Global Assessment (IGA) Response of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) From Week 28 Through Week 40
Week 28 through Week 40
Guselkumab (Randomized)1.5 visits (±1.57 Standard Deviation)
Ustekinumab (Randomized)0.7 visits (±1.26 Standard Deviation)
NCT02407223—Percentage of Participants Who Achieved Assessment of SpondyloArthritis International Society (ASAS) 20 Response at Week 24
Week 24
Placebo47.6 Percentage of participants
Ustekinumab 45 mg55.4 Percentage of participants
Ustekinumab 90 mg49.4 Percentage of participants
NCT02407236
UNIFI
Colitis, UlcerativeInduction Study - Number of Participants With Clinical Remission at Week 8 (As Per Global Definition)
Week 8
Induction Study (IS): Placebo Intravenous (IV)17 Participants
IS: Ustekinumab 130 Milligram (mg) IV50 Participants
IS: Ustekinumab Approximately 6 mg/kg IV50 Participants
NCT02407236
UNIFI
Colitis, UlcerativeInduction Study - Number of Participants With Clinical Remission at Week 8 (As Per US Definition)
Week 8
Induction Study (IS): Placebo Intravenous (IV)20 Participants
IS: Ustekinumab 130 Milligram (mg) IV53 Participants
IS: Ustekinumab Approximately 6 mg/kg IV61 Participants
NCT02407236
UNIFI
Colitis, UlcerativeMaintenance Study: Number of Participants With Clinical Remission at Week 44 (As Per Global Definition)
Week 44
Maintenance Study (MS): Placebo Subcutaneous (SC)42 Participants
MS: Ustekinumab 90 mg SC Every 12 Weeks (q12w)66 Participants
MS: Ustekinumab 90 mg SC Every 8 Weeks (q8w)77 Participants
NCT02407236
UNIFI
Colitis, UlcerativeMaintenance Study: Number of Participants With Clinical Remission at Week 44 (as Per US Definition)
Week 44
Maintenance Study (MS): Placebo Subcutaneous (SC)43 Participants
MS: Ustekinumab 90 mg SC Every 12 Weeks (q12w)68 Participants
MS: Ustekinumab 90 mg SC Every 8 Weeks (q8w)75 Participants
NCT02437162Axial SpondyloarthritisPercentage of Participants Who Achieved an Assessment of Spondyloarthritis International Society (ASAS) 40 Response at Week 24
Week 24
Placebo28.4 Percentage of participants
Ustekinumab 45 Milligram (mg)31.0 Percentage of participants
Ustekinumab 90 mg28.1 Percentage of participants
NCT02438787Spondylitis, AnkylosingPercentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 24
Week(W) 24
Placebo12.3 Percentage of participants
Ustekinumab 45mg19.2 Percentage of participants
Ustekinumab 90mg26.9 Percentage of participants
NCT02561806
IXORA-S
—Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) From Baseline
Week 12
Ixekizumab72.8 percentage of participants
Ustekinumab42.2 percentage of participants
NCT02684357PsoriasisPercentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A)
Week 16
Placebo (Part A)2.0 percentage of participants
Risankizumab (Part A)74.8 percentage of participants
NCT02684357PsoriasisPercentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A)
Week 16
Placebo (Part A)5.1 percentage of participants
Risankizumab (Part A)83.7 percentage of participants
NCT02684370PsoriasisPercentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A)
Week 16
Placebo (Part A)4.9 percentage of participants
Risankizumab (Part A)75.3 percentage of participants
NCT02684370PsoriasisPercentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A)
Week 16
Placebo (Part A)7.8 percentage of participants
Risankizumab (Part A)87.8 percentage of participants
NCT02698475
CADMUS Jr
PsoriasisPercentage of Participants With Physician's Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 12
Week 12
Ustekinumab Standard Dose (Main Study)77.3 percentage of participants
NCT02826603
CLARITY
—Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12
Week 12
Secukinumab 300mg (2 x 150 mg)366 Participants
Ustekinumab 2 x 45mg or 90mg265 Participants
NCT02826603
CLARITY
—Participants With IGA Mod 2011 0 or 1 at Week 12
Week 12
Secukinumab 300mg (2 x 150 mg)397 Participants
Ustekinumab 2 x 45mg or 90mg306 Participants
NCT03107793
STARDUST
Crohn DiseasePercentage of Participants With Endoscopic Response at Week 48
Week 48
Maintenance Period: Routine Care29.9 Percentage of Participants (±23.9 95% Confidence Interval)
Maintenance Period: Treat to Target37.9 Percentage of Participants (±31.4 95% Confidence Interval)
NCT03370133
BE VIVID
PsoriasisPercentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16
Week 16
Bimekizumab 320 mg Q4W (RS)85.0 percentage of participants
Placebo (RS)4.8 percentage of participants
Ustekinumab (RS)49.7 percentage of participants
NCT03370133
BE VIVID
PsoriasisPercentage of Participants With an Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 16
Week 16
Bimekizumab 320 mg Q4W (RS)84.1 percentage of participants
Placebo (RS)4.8 percentage of participants
Ustekinumab (RS)53.4 percentage of participants
NCT03464136
SEAVUE
Crohn DiseasePercentage of Participants With Clinical Remission at Week 52
Week 52
Adalimumab61.0 percentage of participants
Ustekinumab64.9 percentage of participants
NCT03466411
GALAXI
Crohn DiseaseGALAXI 1: Change From Baseline in the Crohn's Disease Activity Index (CDAI) Score at Week 12
Baseline and Week 12
GALAXI 1 (Group 1) Guselkumab 1200 mg IV q4w Followed by 200 mg SC q4w-143.7 Units on a scale (±96.58 Standard Deviation)
GALAXI 1 (Group 2) Guselkumab 600 mg IV q4w Followed by 200 mg SC q4w-139.2 Units on a scale (±100.71 Standard Deviation)
GALAXI 1 (Group 3) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w-159.8 Units on a scale (±110.52 Standard Deviation)
GALAXI 1 (Group 5) Placebo q4w Followed by Placebo q4w-34.4 Units on a scale (±104.85 Standard Deviation)
NCT03466411
GALAXI
Crohn DiseaseGlobal: GALAXI 2: Percentage of Participants With Both Clinical Response (CR) at Week 12 and Endoscopic Response (ER) at Week 48
Weeks 48
GALAXI 2 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w38.4 Percentage of participants
GALAXI 2 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w39.2 Percentage of participants
GALAXI 2 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w5.3 Percentage of participants
NCT03466411
GALAXI
Crohn DiseaseGlobal: GALAXI 2: Percentage of Participants With Both Clinical Response at Week 12 and Clinical Remission at Week 48
Weeks 48
GALAXI 2 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w54.8 Percentage of participants
GALAXI 2 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w49.0 Percentage of participants
GALAXI 2 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w11.8 Percentage of participants
NCT03466411
GALAXI
Crohn DiseaseGlobal: GALAXI 3: Percentage of Participants With Both Clinical Response (CR) at Week 12 and Endoscopic Response (ER) at Week 48
Weeks 48
GALAXI 3 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w36.0 Percentage of participants
GALAXI 3 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w33.6 Percentage of participants
GALAXI 3 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w5.6 Percentage of participants
NCT03466411
GALAXI
Crohn DiseaseGlobal: GALAXI 3: Percentage of Participants With Both Clinical Response at Week 12 and Clinical Remission at Week 48
Weeks 48
GALAXI 3 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w48.0 Percentage of participants
GALAXI 3 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w46.9 Percentage of participants
GALAXI 3 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w12.5 Percentage of participants
NCT03466411
GALAXI
Crohn DiseaseRegional: GALAXI 2: Percentage of Participants With Clinical Remission at Week 12
Week 12
GALAXI 2 Combined Guselkumab 200 mg IV (Group 1+ Group 2)47.1 Percentage of participants
GALAXI 2 Placebo (From Group 4)22.4 Percentage of participants
NCT03466411
GALAXI
Crohn DiseaseRegional: GALAXI 2: Percentage of Participants With Endoscopic Response at Week 12
Week 12
GALAXI 2 Combined Guselkumab 200 mg IV (Group 1+ Group 2)37.7 Percentage of participants
GALAXI 2 Placebo (From Group 4)10.5 Percentage of participants
NCT03466411
GALAXI
Crohn DiseaseRegional: GALAXI 3: Percentage of Participants With Clinical Remission at Week 12
Week 12
GALAXI 3 Combined Guselkumab 200 mg IV (Group 1+ Group 2)47.1 Percentage of participants
GALAXI 3 Placebo (From Group 4)15.3 Percentage of participants
NCT03466411
GALAXI
Crohn DiseaseRegional: GALAXI 3: Percentage of Participants With Endoscopic Response at Week 12
Week 12
GALAXI 3 Combined Guselkumab 200 mg IV (Group 1+ Group 2)36.2 Percentage of participants
GALAXI 3 Placebo (From Group 4)13.9 Percentage of participants
NCT03517722Lupus Erythematosus, SystemicPercentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index-4 (SRI-4) Composite Response at Week 52
Week 52
Placebo to Ustekinumab56.0 percentage of participants
Ustekinumab43.9 percentage of participants
NCT03782376
POWER
Crohn DiseasePercentage of Participants With Clinical Response at Week 16
Week 16
Group 1: Ustekinumab (IV Re-induction)49.1 Percentage of participants
Group 2: Ustekinumab (Continuous q8w SC Maintenance)37.4 Percentage of participants
NCT03926130
VIVID-1
Crohn DiseasePercentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission at Week 52 (Placebo and Mirikizumab)
Week 12 to Week 52
Mirikizumab45.4 percentage of participants
Placebo19.6 percentage of participants
NCT03926130
VIVID-1
Crohn DiseasePercentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab)
Week 12 to Week 52
Mirikizumab38.0 percentage of participants
Placebo9.0 percentage of participants
NCT03981744DermatomyositisPercentage of Participants Who Achieved Minimal Improvement in International Myositis Assessment and Clinical Studies Total Improvement Score (IMACS TIS) at Week 24
Week 24
Placebo61.5 Percentage of participants
Ustekinumab64.0 Percentage of participants
NCT04245215
REScUE
Crohn DiseaseProportion of Patients With Steroid Free Clinical Remission and Fecal Calprotectin<250µg/g at Week 48
week 48
Ustekinumab q4w8 Participants
Ustekinumab q8w10 Participants
NCT04305327
EMBRACE 1
PsoriasisPsoriasis Area and Severity Index (PASI) 75 Response, Assessed at Week 12.
Baseline to Week 12
BrodalumabNA Participants
Placebo/UstekinumabNA Participants
NCT04435600
OptIMMize-1
PsoriasisPercentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 (Defined as at Least 75% Improvement in PASI)
Baseline (Week 0) to Week 16 of initial treatment in each part of the study (Parts 1-4)
Part 1: Risankizumab83.3 percentage of participants
Part 2 Period A: Risankizumab85.2 percentage of participants
Part 2 Period A: Ustekinumab85.7 percentage of participants
Part 3: Risankizumab92.3 percentage of participants
Part 4: Risankizumab86.7 percentage of participants
NCT04435600
OptIMMize-1
PsoriasisPercentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1)
At Week 16 of initial treatment in each part of the study (Parts 1-4)
Part 1: Risankizumab83.3 percentage of participants
Part 2 Period A: Risankizumab79.6 percentage of participants
Part 2 Period A: Ustekinumab75.0 percentage of participants
Part 3: Risankizumab84.6 percentage of participants
Part 4: Risankizumab90.0 percentage of participants
NCT04435600
OptIMMize-1
PsoriasisPercentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1) and With at Least 2 Grade Improvement From Baseline
Baseline (Week 0) to Week 16 of initial treatment in each part of the study (Parts 1-4)
Part 1: Risankizumab83.3 percentage of participants
Part 2 Period A: Risankizumab68.5 percentage of participants
Part 2 Period A: Ustekinumab67.9 percentage of participants
Part 2 Period C: Risankizumab0.0 percentage of participants
Part 2 Period C: Risankizumab62.5 percentage of participants
Part 3: Risankizumab84.6 percentage of participants
Part 4: Risankizumab83.3 percentage of participants
NCT04607980PsoriasisPASI Percent Change From Baseline to Week 12
Baseline (Day 1 [Week 0]) and Week 12
Treatment Group A (ABP 654)81.92 Percent Change in PASI score (±19.872 Standard Deviation)
Treatment Group B (Ustekinumab)81.91 Percent Change in PASI score (±19.611 Standard Deviation)
NCT04632927
AgAIN
Arthritis, PsoriaticProportion of Patients With Health Assessment Questionnaire - Disability Index (HAQ-DI) Response at Week 28
Baseline, Week 28
Secukinumab32 Participants
Ustekinumab17 Participants
NCT04761627PsoriasisArea Under the Plasma Concentration Time Curve (AUC) Over the Dosing Interval (AUCtau) Between Week 52 and Week 64
Blood samples were taken pre-dose week 52; and at 2 days, 7 days, 10 days, 2 weeks, 4 weeks, 8 weeks, and 12 weeks after the week 52 dose
Post-randomization Continued-use: Ustekinumab RP5768.45 hour*mcg/mL (±50.4 Geometric Coefficient of Variation)
Post-randomization Switching: Ustekinumab RP and ABP 6545144.40 hour*mcg/mL (±45.3 Geometric Coefficient of Variation)
NCT04761627PsoriasisMaximum Observed Serum Concentration (Cmax) Between Week 52 and Week 64
Blood samples were taken pre-dose week 52; and at 2 days, 7 days, 10 days, 2 weeks, 4 weeks, 8 weeks, and 12 weeks after the week 52 dose
Post-randomization Continued-use: Ustekinumab RP6.31 mcg/mL (±46.8 Geometric Coefficient of Variation)
Post-randomization Switching: Ustekinumab RP and ABP 6545.78 mcg/mL (±41.4 Geometric Coefficient of Variation)
NCT04882072Takayasu ArteritisTime to Relapse (ToR) of Takayasu Arteritis (TAK) According to Protocol-defined Criteria Through the End of Double-blind Period
From double-blind Week 0 up to end of double-blind period (up to 71.1 weeks)
Double-blind: Placebo12.64 Weeks
Double-blind: Ustekinumab11.14 Weeks
NCT04967508PsoriasisPercent Change From Baseline in PASI at Week 12
Baseline and Week 12
SB17 (Proposed Ustekinumab Biosimilar)85.7 Percent change (±2.53 Standard Error)
Stelara (Ustekinumab)86.3 Percent change (±2.41 Standard Error)

Publications by year

1978–2026: 325 publications.

1978
1
1999
1
2002
2
2003
1
2004
3
2005
2
2006
3
2007
7
2008
11
2009
4
2010
7
2011
13
2012
10
2013
12
2014
12
2015
16
2016
19
2017
17
2018
19
2019
16
2020
13
2021
25
2022
38
2023
17
2024
19
2025
26
2026
11

Publications by indication

Crohn Disease (154)

  • Effectiveness and safety of ustekinumab in pediatric Crohn's disease: Results of the REALITI study.
    J Pediatr Gastroenterol Nutr · 2026 · PMID 41766590 · NCT05242458
  • The Effect of Dose Intensification After Secondary Loss of Response to Ustekinumab in Crohn's Disease: Results of the REScUE Study.
    Gastroenterology · 2026 · PMID 41747777 · NCT04245215
  • Bowel Urgency in Crohn's Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Study.
    Clin Gastroenterol Hepatol · 2026 · PMID 40669578 · NCT03926130
  • Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg.
    J Crohns Colitis · 2026 · PMID 41843763 · NCT04673357
  • Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial.
    Inflamm Bowel Dis · 2026 · PMID 42065683 · NCT03466411

Psoriasis (65)

  • Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability.
    J Allergy Clin Immunol · 2026 · PMID 41580158 · NCT03370133
  • Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years.
    J Dermatolog Treat · 2026 · PMID 41800601 · NCT03370133
  • Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT.
    Dermatol Ther (Heidelb) · 2026 · PMID 41359217 · NCT03370133
  • Pharmacokinetics and Safety of Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Results of the Real-World Ustekinumab Pediatric Opportunistic Pharmacokinetics Study (U-POPS).
    Rheumatol Ther · 2026 · PMID 41452420 · NCT05252533
  • Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials.
    Dermatol Ther (Heidelb) · 2025 · PMID 41060492 · NCT03370133

Colitis, Ulcerative (30)

  • Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-line Therapy in Anti-tumor Necrosis Factor-experienced Patients With Ulcerative Colitis.
    Clin Gastroenterol Hepatol · 2026 · PMID 41616901 · NCT06691061
  • Responsiveness of different disease activity indices in moderate-to-severe ulcerative colitis.
    Med · 2025 · PMID 39368474 · NCT02407236
  • Clinical Trial: Association Between Early Disease Clearance and Long-Term Outcomes-4-Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis.
    Aliment Pharmacol Ther · 2025 · PMID 40668079 · NCT02407236
  • Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study.
    Am J Gastroenterol · 2024 · PMID 38095692 · NCT02407236
  • Trajectory of fecal lactoferrin for predicting prognosis in ulcerative colitis.
    Precis Clin Med · 2023 · PMID 38025971 · NCT02407236

Alzheimer Disease (26)

  • The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.
    J Prev Alzheimers Dis · 2024 · PMID 26478889 · NCT02835716
  • Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a 'European ADNI study'.
    J Intern Med · 2017 · PMID 26940242 · NCT02835716
  • Targeting neuroinflammation in Alzheimer's disease: evidence for NSAIDs and novel therapeutics.
    Expert Rev Neurother · 2017 · PMID 27293026 · NCT02835716
  • The Biomarkers for Identifying Preclinical Alzheimer's Disease via Structural and Functional Magnetic Resonance Imaging.
    Front Aging Neurosci · 2016 · PMID 27199739 · NCT02835716
  • Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease.
    Neurotherapeutics · 2016 · PMID 25371167 · NCT02835716

Lupus Erythematosus, Systemic (6)

  • Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus.
    Ann Rheum Dis · 2025 · PMID 35798534 · NCT03517722
  • Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study.
    J Rheumatol · 2022 · PMID 34853089 · NCT02349061
  • Interventions for cutaneous disease in systemic lupus erythematosus.
    Cochrane Database Syst Rev · 2021 · PMID 33687069 · NCT03517722
  • Suppression of Serum Interferon-γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus.
    Arthritis Rheumatol · 2021 · PMID 33010188 · NCT02349061
  • Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus.
    Arthritis Rheumatol · 2020 · PMID 31769212 · NCT02349061

Arthritis, Psoriatic (6)

  • Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial.
    Lancet Rheumatol · 2024 · PMID 38251504 · NCT03148860
  • Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis.
    J Rheumatol · 2023 · PMID 36642439 · NCT02319759
  • The role of antidrug antibodies in ustekinumab therapy and the impact of methotrexate.
    Rheumatology (Oxford) · 2023 · PMID 37079726 · NCT03148860
  • Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.
    RMD Open · 2021 · PMID 32665433 · NCT02319759
  • Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial.
    Arthritis Care Res (Hoboken) · 2020 · PMID 31421033 · NCT02319759

Publications by journal

Trial-results highlights

In studies evaluating Ustekinumab for psoriasis, several trials assessed the Psoriasis Area-and-severity Index (PASI) 75% improvement from baseline at week 12.

  • In NCT00267969 (PHOENIX 1), 171 participants on Ustekinumab 45 mg and 170 participants on Ustekinumab 90 mg achieved this endpoint, compared to 8 participants on placebo.
  • NCT00307437 reported 273 participants on Ustekinumab 45 mg and 311 participants on Ustekinumab 90 mg achieved PASI 75% improvement, versus 15 participants on placebo.
  • In NCT00747344, 41 participants on Ustekinumab 45 mg achieved at least a 75% improvement in PASI at week 12, compared to 3 participants on placebo.
  • NCT01008995 showed 132 participants on Ustekinumab 45 mg achieved at least a 75% improvement in PASI from baseline at week 12, versus 18 participants on placebo.
Regarding percentages, NCT00723528 reported 59.4% of participants on Ustekinumab 45 mg and 67.7% on Ustekinumab 90 mg achieved greater than or equal to 75% improvement in PASI score at week 12, while 6.5% of participants on placebo achieved this.

Another psoriasis trial, NCT01090427, evaluated the percentage of participants achieving a Physician's Global Assessment (PGA) score of cleared (0) or minimal (1) at week 12. In this study, 67.6% of participants on Ustekinumab Half-Standard Dosage and 69.4% on Ustekinumab Standard Dosage achieved this outcome, compared to 5.4% on placebo.

For psoriatic arthritis, two trials assessed the American College of Rheumatology (ACR) 20 response at week 24. In NCT01009086, 46.0% of participants in the combined Ustekinumab group achieved an ACR 20 response. Specifically, 42.4% on Ustekinumab 45 mg and 49.5% on Ustekinumab 90 mg achieved this, compared to 22.8% on placebo. Similarly, NCT01077362 reported 43.8% of participants in the combined Ustekinumab group achieved an ACR 20 response, with 43.7% on Ustekinumab 45 mg and 43.8% on Ustekinumab 90 mg, versus 20.2% on placebo.

All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Ustekinumab publications (325)

2026 (11 papers)

  1. Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability.
    Krueger JG, Cutcutache I, Lebwohl M, et al. · J Allergy Clin Immunol · 2026 · Trial result
    PubMed: PMID 41580158 · NCT03370133 (BE VIVID) · Psoriasis
  2. Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years.
    Gisondi P, Elewski B, Pinter A, et al. · J Dermatolog Treat · 2026 · Trial result
    PubMed: PMID 41800601 · NCT03370133 (BE VIVID) · Psoriasis
  3. Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT.
    Armstrong A, Papp KA, Lebwohl M, et al. · Dermatol Ther (Heidelb) · 2026 · Trial result
    PubMed: PMID 41359217 · NCT03370133 (BE VIVID) · Psoriasis
  4. Effectiveness and safety of ustekinumab in pediatric Crohn's disease: Results of the REALITI study.
    Steiner SJ, Adler J, Saeed SA, et al. · J Pediatr Gastroenterol Nutr · 2026 · Derived
    PubMed: PMID 41766590 · NCT05242458 (REALITI) · Crohn Disease
  5. Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-line Therapy in Anti-tumor Necrosis Factor-experienced Patients With Ulcerative Colitis.
    Privitera G, Bezzio C, Figlioli G, et al. · Clin Gastroenterol Hepatol · 2026 · Derived
    PubMed: PMID 41616901 · NCT06691061 · Colitis, Ulcerative
  6. The Effect of Dose Intensification After Secondary Loss of Response to Ustekinumab in Crohn's Disease: Results of the REScUE Study.
    Bossuyt P, Rahier JF, Baert F, et al. · Gastroenterology · 2026 · Derived
    PubMed: PMID 41747777 · NCT04245215 (REScUE) · Crohn Disease
  7. Pharmacokinetics and Safety of Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Results of the Real-World Ustekinumab Pediatric Opportunistic Pharmacokinetics Study (U-POPS).
    Lam E, Berezny K, Bishop CJ, et al. · Rheumatol Ther · 2026 · Derived
    PubMed: PMID 41452420 · NCT05252533 (U-POPS) · Psoriasis
  8. Bowel Urgency in Crohn's Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Study.
    Jairath V, D'Haens G, Sands BE, et al. · Clin Gastroenterol Hepatol · 2026 · Derived
    PubMed: PMID 40669578 · NCT03926130 (VIVID-1) · Crohn Disease
  9. Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg.
    De Greef E, Turner D, Kierkuś J, et al. · J Crohns Colitis · 2026 · Derived
    PubMed: PMID 41843763 · NCT04673357 (UNITI Jr) · Crohn Disease
  10. Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial.
    Afzali A, Danese S, Panaccione R, et al. · Inflamm Bowel Dis · 2026 · Derived
    PubMed: PMID 42065683 · NCT03466411 (GALAXI) · Crohn Disease
  11. Dual biological therapy and small molecules in pediatric inflammatory bowel disease.
    Penagini F, Lonoce L, Abbattista L, et al. · Pharmacol Res · 2026 · Background
    PubMed: PMID 37748559 · NCT06520397 · Crohn Disease

2025 (26 papers)

  1. Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials.
    Strober B, Boehncke WH, Krueger JG, et al. · Dermatol Ther (Heidelb) · 2025 · Trial result
    PubMed: PMID 41060492 · NCT03370133 (BE VIVID) · Psoriasis
  2. Phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study of ustekinumab in patients with Takayasu arteritis.
    Yoshifuji H, Ishii T, Ohashi H, et al. · Rheumatol Adv Pract · 2025 · Derived
    PubMed: PMID 40104212 · NCT04882072 · Takayasu Arteritis
  3. Serum protein profiles differ with adalimumab and ustekinumab treatment in moderately to severely active Crohn's disease.
    Venkat S, Zeeman M, Hart A, et al. · J Crohns Colitis · 2025 · Derived
    PubMed: PMID 41258994 · NCT03464136 (SEAVUE) · Crohn Disease
  4. Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus.
    van Vollenhoven RF, Kalunian KC, Dörner T, et al. · Ann Rheum Dis · 2025 · Derived
    PubMed: PMID 35798534 · NCT03517722 · Lupus Erythematosus, Systemic
  5. Responsiveness of different disease activity indices in moderate-to-severe ulcerative colitis.
    Solitano V, Panaccione R, Sands BE, et al. · Med · 2025 · Derived
    PubMed: PMID 39368474 · NCT02407236 (UNIFI) · Colitis, Ulcerative
  6. Psychometric evaluation of the Functional Assessment of chronic illness therapy-fatigue (FACIT-Fatigue) in adults with moderately to severely active Crohn's disease.
    Regueiro M, Su S, Vadhariya A, et al. · Qual Life Res · 2025 · Derived
    PubMed: PMID 39537976 · NCT03926130 (VIVID-1) · Crohn Disease
  7. Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn's disease: results from the phase 3 VIVID-1 study.
    Regueiro M, Fischer M, Bossuyt P, et al. · J Crohns Colitis · 2025 · Derived
    PubMed: PMID 40491246 · NCT03926130 (VIVID-1) · Crohn Disease
  8. Efficacy and safety of risankizumab in patients with moderately to severely active Crohn's disease: interim results from the SEQUENCE open-label extension study.
    Peyrin-Biroulet L, Atreya R, Danese S, et al. · J Crohns Colitis · 2025 · Derived
    PubMed: PMID 41344313 · NCT04524611 (SEQUENCE) · Crohn Disease
  9. A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis.
    Papp K, Balser S, Nopora K, et al. · Adv Ther · 2025 · Derived
    PubMed: PMID 40048101 · NCT04595409 (VESPUCCI)
  10. Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials.
    Panaccione R, Feagan BG, Afzali A, et al. · Lancet · 2025 · Derived
    PubMed: PMID 40684778 · NCT03466411 (GALAXI) · Crohn Disease
  11. Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies.
    Merola JF, Warren RB, Thaçi D, et al. · Am J Clin Dermatol · 2025 · Derived
    PubMed: PMID 40886218 · NCT03370133 (BE VIVID) · Psoriasis
  12. Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials.
    Merola JF, Gottlieb AB, Pinter A, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
    PubMed: PMID 39578348 · NCT03370133 (BE VIVID) · Psoriasis
  13. Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
    Mease PJ, Warren RB, Nash P, et al. · Rheumatol Ther · 2025 · Derived
    PubMed: PMID 39120848 · NCT01077362 · Psoriasis
  14. A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes.
    Marwaha AK, Chow S, Pesenacker AM, et al. · Immunother Adv · 2025 · Derived
    PubMed: PMID 35072168 · NCT02117765 (UST1D) · Diabetes Mellitus, Type 1
  15. A patient-reported outcome measure comprising the stool frequency and abdominal pain items from the Crohn's Disease Activity Index: psychometric evaluation in adults with Crohn's disease.
    Lewis JD, Vadhariya A, Su S, et al. · J Patient Rep Outcomes · 2025 · Derived
    PubMed: PMID 39962027 · NCT03926130 (VIVID-1) · Crohn Disease
  16. Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study.
    Lee SD, Vermeire S, Ungaro R, et al. · Am J Gastroenterol · 2025 · Derived
    PubMed: PMID 40079470 · NCT03926130 (VIVID-1) · Crohn Disease
  17. One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn's Disease: The K-STAR Study.
    Lee CK, Moon W, Chun J, et al. · Inflamm Bowel Dis · 2025 · Derived
    PubMed: PMID 39096895 · NCT03942120 (STELARA CD PMS) · Crohn Disease
  18. A Review of the Modified Multiplier of Simple Endoscopic Score for Crohn's Disease and How to Use It in Clinical Trials and Practice.
    Huan PW, Mehta A, Wong ECL, et al. · Am J Gastroenterol · 2025 · Derived
    PubMed: PMID 39996607 · NCT01369329 · Crohn Disease
  19. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Hasskamp J, Meinhardt C, Timmer A, et al. · Cochrane Database Syst Rev · 2025 · Derived
    PubMed: PMID 40357993 · NCT02968108 (STELARA) · Crohn Disease
  20. MOdel-informed precision dosing (MIPD) of ustekinumab and VEdolizumab in inflammatory bowel disease: protocol for an Independent randomised, controlled, multicentre Trial (MOVE-IT).
    Frimor C, Steenholdt C, Widigson ESK, et al. · BMJ Open Gastroenterol · 2025 · Derived
    PubMed: PMID 41453773 · NCT06788340 (MOVE-IT) · Crohn Disease
  21. The Urgency Numeric Rating Scale: Psychometric Evaluation in Adults with Crohn's Disease.
    Dubinsky M, Vadhariya A, Su S, et al. · Adv Ther · 2025 · Derived
    PubMed: PMID 39692838 · NCT03926130 (VIVID-1) · Crohn Disease
  22. Efficacy and Safety of Deucravacitinib, a Selective, Allosteric TYK2 Inhibitor, by Baseline DMARD Use in a Phase 2 Psoriatic Arthritis Study: A Post Hoc Analysis.
    Deodhar A, Nowak M, Ye JY, et al. · Rheumatol Ther · 2025 · Derived
    PubMed: PMID 40616721 · NCT03881059
  23. Clinical Trial: Association Between Early Disease Clearance and Long-Term Outcomes-4-Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis.
    Danese S, Leong RW, Sands BE, et al. · Aliment Pharmacol Ther · 2025 · Derived
    PubMed: PMID 40668079 · NCT02407236 (UNIFI) · Colitis, Ulcerative
  24. Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks.
    Blauvelt A, Papp K, Trivedi M, et al. · Br J Dermatol · 2025 · Derived
    PubMed: PMID 39442018 · NCT04607980 · Psoriasis
  25. New Interleukin-23 Antagonists' Use in Crohn's Disease.
    Biskup L, Semeradt J, Rogowska J, et al. · Pharmaceuticals (Basel) · 2025 · Background
    PubMed: PMID 40283885 · NCT07495644 · Crohn Disease
  26. Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease.
    Alayo QA, Fenster M, Altayar O, et al. · Crohns Colitis 360 · 2025 · Background
    PubMed: PMID 35310082 · NCT06520397 · Crohn Disease

2024 (19 papers)

  1. CT venography for the diagnosis of postpartum venous thromboembolism: a prospective multi-center cohort study.
    Revel MP, Chassagnon G, Sanchez O, et al. · Eur Radiol · 2024 · Trial result
    PubMed: PMID 38782788 · NCT02648581 (STELABEC) · Uveitis
  2. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
    Gordon KB, Langley RG, Warren RB, et al. · Br J Dermatol · 2024 · Trial result
    PubMed: PMID 37950894 · NCT03370133 (BE VIVID) · Psoriasis
  3. Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials.
    Warren RB, Gottlieb AB, Merola JF, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 34260044 · NCT03370133 (BE VIVID) · Psoriasis
  4. Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
    Strober B, Coates LC, Lebwohl MG, et al. · Drug Saf · 2024 · Derived
    PubMed: PMID 37906417 · NCT02203032 (NAVIGATE) · Psoriasis
  5. Improvements in Patient-Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial.
    Strand V, Gossec L, Coates LC, et al. · Arthritis Care Res (Hoboken) · 2024 · Derived
    PubMed: PMID 38529674 · NCT03881059
  6. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
    Peyrin-Biroulet L, Chapman JC, Colombel JF, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 39018531 · NCT04524611 (SEQUENCE) · Crohn Disease
  7. Efficacy and Safety of Ustekinumab for Chronic Pouchitis: A Prospective Open-label Multicenter Study.
    Outtier A, Louis E, Dewit O, et al. · Clin Gastroenterol Hepatol · 2024 · Derived
    PubMed: PMID 38750870 · NCT04089345 (SOCRATES) · Pouchitis
  8. Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses.
    Lebwohl MG, Armstrong AW, Alexis AF, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 39264399 · NCT01708603 (AMAGINE-2) · Psoriasis
  9. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial.
    Koehm M, Rossmanith T, Foldenauer AC, et al. · Lancet Rheumatol · 2024 · Derived
    PubMed: PMID 38251504 · NCT03148860 (MUST) · Arthritis, Psoriatic
  10. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis.
    Ghosh S, Feagan BG, Ott E, et al. · J Crohns Colitis · 2024 · Derived
    PubMed: PMID 38310565 · NCT01369329 · Crohn Disease
  11. Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses.
    FitzGerald O, Gladman DD, Mease PJ, et al. · Arthritis Rheumatol · 2024 · Derived
    PubMed: PMID 38770592 · NCT03881059
  12. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
    Ferrante M, D'Haens G, Jairath V, et al. · Lancet · 2024 · Derived
    PubMed: PMID 39581202 · NCT03926130 (VIVID-1) · Crohn Disease
  13. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
    Danese S, Panaccione R, Feagan BG, et al. · Lancet Gastroenterol Hepatol · 2024 · Derived
    PubMed: PMID 38104569 · NCT03466411 (GALAXI) · Crohn Disease
  14. Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
    Armstrong A, González-Cantero A, Khattri S, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 38521874 · NCT02561806 (IXORA-S)
  15. Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study.
    Afif W, Arasaradnam RP, Abreu MT, et al. · Am J Gastroenterol · 2024 · Derived
    PubMed: PMID 38095692 · NCT02407236 (UNIFI) · Colitis, Ulcerative
  16. Dual Biologic or Small Molecule Therapy in Refractory Pediatric Inflammatory Bowel Disease (DOUBLE-PIBD): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN.
    Yerushalmy-Feler A, Olbjorn C, Kolho KL, et al. · Inflamm Bowel Dis · 2024 · Background
    PubMed: PMID 37042978 · NCT06520397 · Crohn Disease
  17. Immunogenicity of biologics in inflammatory bowel disease.
    Vermeire S, Gils A, Accossato P, et al. · Ther Adv Gastroenterol · 2024 · Background
    PubMed: PMID 29383030 · NCT07495644 · Crohn Disease
  18. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
    Noor NM, Lee JC, Bond S, et al. · Lancet Gastroenterol Hepatol · 2024 · Background
    PubMed: PMID 38402895 · NCT06520397 · Crohn Disease
  19. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.
    Cavedo E, Lista S, Khachaturian Z, et al. · J Prev Alzheimers Dis · 2024 · Background
    PubMed: PMID 26478889 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease

2023 (17 papers)

  1. Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study.
    Asahina A, Okubo Y, Morita A, et al. · Dermatol Ther (Heidelb) · 2023 · Trial result
    PubMed: PMID 36648594 · NCT03370133 (BE VIVID) · Psoriasis
  2. Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis.
    Rahman P, Boehncke WH, Mease PJ, et al. · J Rheumatol · 2023 · Derived
    PubMed: PMID 36642439 · NCT02319759 · Arthritis, Psoriatic
  3. Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST.
    Peyrin-Biroulet L, Vermeire S, D'Haens G, et al. · Aliment Pharmacol Ther · 2023 · Derived
    PubMed: PMID 38036946 · NCT03107793 (STARDUST) · Crohn Disease
  4. The microbiome in HLA-B27-associated disease: implications for acute anterior uveitis and recommendations for future studies.
    Parthasarathy R, Santiago F, McCluskey P, et al. · Trends Microbiol · 2023 · Derived
    PubMed: PMID 36058784 · NCT01330901 (TOPAS) · Spondylitis, Ankylosing
  5. The role of antidrug antibodies in ustekinumab therapy and the impact of methotrexate.
    Mojtahed Poor S, Henke M, Ulshöfer T, et al. · Rheumatology (Oxford) · 2023 · Derived
    PubMed: PMID 37079726 · NCT03148860 (MUST) · Arthritis, Psoriatic
  6. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
    Kokolakis G, Warren RB, Strober B, et al. · Br J Dermatol · 2023 · Derived
    PubMed: PMID 36751950 · NCT03370133 (BE VIVID) · Psoriasis
  7. Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group study of ustekinumab in Japanese patients with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments.
    Kawahata K, Ishii T, Gono T, et al. · RMD Open · 2023 · Derived
    PubMed: PMID 37652554 · NCT03981744 · Dermatomyositis
  8. Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials.
    Kavanaugh A, Baraliakos X, Gao S, et al. · Adv Ther · 2023 · Derived
    PubMed: PMID 36995469 · NCT02438787 · Spondylitis, Ankylosing
  9. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
    Dubinsky M, Ma C, Griffith J, et al. · Adv Ther · 2023 · Derived
    PubMed: PMID 37368103 · NCT01369342 · Crohn Disease
  10. Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease.
    Colombel JF, Sands BE, Gasink C, et al. · Clin Gastroenterol Hepatol · 2023 · Derived
    PubMed: PMID 37391056 · NCT01369329 · Crohn Disease
  11. Trajectory of fecal lactoferrin for predicting prognosis in ulcerative colitis.
    Chen R, Li L, Tie Y, et al. · Precis Clin Med · 2023 · Derived
    PubMed: PMID 38025971 · NCT02407236 (UNIFI) · Colitis, Ulcerative
  12. Guselkumab More Effectively Neutralizes Psoriasis-Associated Histologic, Transcriptomic, and Clinical Measures than Ustekinumab.
    Campbell K, Li K, Yang F, et al. · Immunohorizons · 2023 · Derived
    PubMed: PMID 37071038 · NCT02203032 (NAVIGATE) · Psoriasis
  13. A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn's Disease.
    Allez M, Sands BE, Feagan BG, et al. · J Crohns Colitis · 2023 · Derived
    PubMed: PMID 36939629 · NCT02877134 (TRIDENT) · Crohn Disease
  14. First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Nonsmall Cell Lung Cancer.
    Tsai LL, Phillips WW, Hung YP, et al. · Ann Surg · 2023 · Background
    PubMed: PMID 35129472 · NCT07352566 · Psoriasis
  15. Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
    Peruzzi P, Dominas C, Fell G, et al. · Sci Transl Med · 2023 · Background
    PubMed: PMID 37672566 · NCT07352566 · Psoriasis
  16. Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.
    Loftus EV, Panés J, Lacerda AP, et al. · N Engl J Med · 2023 · Background
    PubMed: PMID 37224198 · NCT06520397 · Crohn Disease
  17. Breaking through the therapeutic ceiling of inflammatory bowel disease: Dual-targeted therapies.
    Feng Z, Kang G, Wang J, et al. · Biomed Pharmacother · 2023 · Background
    PubMed: PMID 36587559 · NCT06520397 · Crohn Disease

2022 (38 papers)

  1. Efficacy and safety of ustekinumab in Behçet disease: Results from the prospective phase 2 STELABEC trial.
    London J, Régent A, Dion J, et al. · J Am Acad Dermatol · 2022 · Trial result
    PubMed: PMID 34864108 · NCT02648581 (STELABEC) · Uveitis
  2. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
    Gordon KB, Langley RG, Warren RB, et al. · JAMA Dermatol · 2022 · Trial result
    PubMed: PMID 35544084 · NCT03370133 (BE VIVID) · Psoriasis
  3. Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study.
    van Vollenhoven RF, Hahn BH, Tsokos GC, et al. · J Rheumatol · 2022 · Derived
    PubMed: PMID 34853089 · NCT02349061 · Lupus Erythematosus, Systemic
  4. Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease.
    Ten Bokkel Huinink S, Biemans V, Duijvestein M, et al. · Eur J Gastroenterol Hepatol · 2022 · Derived
    PubMed: PMID 34334713 · NCT03782376 (POWER) · Crohn Disease
  5. Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders.
    Strober B, Armstrong A, Rubant S, et al. · J Dermatolog Treat · 2022 · Derived
    PubMed: PMID 35839335 · NCT02684370 · Psoriasis
  6. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
    Sands BE, Irving PM, Hoops T, et al. · Lancet · 2022 · Derived
    PubMed: PMID 35691323 · NCT03464136 (SEAVUE) · Crohn Disease
  7. Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial.
    Sandborn WJ, Rebuck R, Wang Y, et al. · Clin Gastroenterol Hepatol · 2022 · Derived
    PubMed: PMID 33618023 · NCT01369355 · Crohn Disease
  8. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies.
    Sandborn WJ, Feagan BG, Danese S, et al. · Inflamm Bowel Dis · 2022 · Derived
    PubMed: PMID 32964215 · NCT01369342 · Crohn Disease
  9. Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
    Sandborn WJ, D'Haens GR, Reinisch W, et al. · Gastroenterology · 2022 · Derived
    PubMed: PMID 35134323 · NCT03466411 (GALAXI) · Crohn Disease
  10. Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease.
    Narula N, Wong ECL, Dulai PS, et al. · Am J Gastroenterol · 2022 · Derived
    PubMed: PMID 35435862 · NCT01369329 · Crohn Disease
  11. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies.
    Narula N, Aruljothy A, Wong ECL, et al. · United European Gastroenterol J · 2022 · Derived
    PubMed: PMID 34077627 · NCT01369355 · Crohn Disease
  12. Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications.
    Merola JF, McInnes IB, Deodhar AA, et al. · Rheumatol Ther · 2022 · Derived
    PubMed: PMID 35305260 · NCT02074982 · Dermatitis
  13. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.
    Mease PJ, Deodhar AA, van der Heijde D, et al. · Ann Rheum Dis · 2022 · Derived
    PubMed: PMID 35241426 · NCT03881059
  14. Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study.
    Matsuoka K, Nagano K, Nagasaki S, et al. · BMJ Open · 2022 · Derived
    PubMed: PMID 35508346 · NCT04963725 · Colitis, Ulcerative
  15. Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations.
    Leu JH, Shiff NJ, Clark M, et al. · Paediatr Drugs · 2022 · Derived
    PubMed: PMID 36171515 · NCT02698475 (CADMUS Jr) · Psoriasis
  16. Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials.
    Lebwohl MG, Soliman AM, Yang H, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
    PubMed: PMID 34921669 · NCT02684357 · Psoriasis
  17. Early Ultrasound Response and Progressive Transmural Remission After Treatment With Ustekinumab in Crohn's Disease.
    Kucharzik T, Wilkens R, D'Agostino MA, et al. · Clin Gastroenterol Hepatol · 2022 · Derived
    PubMed: PMID 35842121 · NCT03107793 (STARDUST) · Crohn Disease
  18. Endothelial glycocalyx and microvascular perfusion are associated with carotid intima-media thickness and impaired myocardial deformation in psoriatic disease.
    Ikonomidis I, Pavlidis G, Lambadiari V, et al. · J Hum Hypertens · 2022 · Derived
    PubMed: PMID 34819613 · NCT02144857 · Psoriasis
  19. Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies.
    Hibi T, Imai Y, Murata Y, et al. · Intest Res · 2022 · Derived
    PubMed: PMID 29142515 · NCT01369329 · Crohn Disease
  20. Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical Trial.
    Harris KM, Smilek DE, Byron M, et al. · JAMA Dermatol · 2022 · Derived
    PubMed: PMID 34643650 · NCT01999868 (PAUSE) · Psoriasis
  21. Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
    Elewski BE, Blauvelt A, Gallo G, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
    PubMed: PMID 35279805 · NCT02561806 (IXORA-S)
  22. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
    Danese S, Vermeire S, D'Haens G, et al. · Lancet Gastroenterol Hepatol · 2022 · Derived
    PubMed: PMID 35120656 · NCT03107793 (STARDUST) · Crohn Disease
  23. Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial.
    Danese S, Sands BE, Abreu MT, et al. · Clin Gastroenterol Hepatol · 2022 · Derived
    PubMed: PMID 35276329 · NCT02407236 (UNIFI) · Colitis, Ulcerative
  24. Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis.
    Conrad C, Ortmann CE, Vandemeulebroecke M, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
    PubMed: PMID 34870789 · NCT02074982 · Dermatitis
  25. Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region.
    Alpalhão M, Duarte J, Diogo R, et al. · BioDrugs · 2022 · Derived
    PubMed: PMID 36334236 · NCT02826603 (CLARITY)
  26. Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease.
    Adedokun OJ, Xu Z, Gasink C, et al. · Clin Ther · 2022 · Derived
    PubMed: PMID 36150926 · NCT00771667 · Crohn Disease
  27. A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs.
    Tatarova Z, Blumberg DC, Korkola JE, et al. · Nat Biotechnol · 2022 · Background
    PubMed: PMID 35788566 · NCT07352566 · Psoriasis
  28. Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease.
    Stalgis C, Deepak P, Mehandru S, et al. · Gastroenterology · 2022 · Background
    PubMed: PMID 33961886 · NCT06520397 · Crohn Disease
  29. Breaking Through the Therapeutic Ceiling: What Will It Take?
    Raine T, Danese S · Gastroenterology · 2022 · Background
    PubMed: PMID 34995533 · NCT06520397 · Crohn Disease
  30. Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey.
    Parigi TL, D'Amico F, Abreu MT, et al. · Lancet Gastroenterol Hepatol · 2022 · Background
    PubMed: PMID 35397241 · NCT06520397 · Crohn Disease
  31. Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment.
    Lee SH, Walshe M, Oh EH, et al. · Inflamm Bowel Dis · 2022 · Background
    PubMed: PMID 33269403 · NCT05186623 · Colitis, Ulcerative
  32. Safety and Efficacy of Tofacitinib in Combination With Biologic Therapy for Refractory Crohn's Disease.
    Lee SD, Singla A, Harper J, et al. · Inflamm Bowel Dis · 2022 · Background
    PubMed: PMID 34347103 · NCT06520397 · Crohn Disease
  33. Adjunct Thrombolysis Enhances Brain Reperfusion following Successful Thrombectomy.
    Laredo C, Rodríguez A, Oleaga L, et al. · Ann Neurol · 2022 · Background
    PubMed: PMID 36054449 · NCT07495644 · Crohn Disease
  34. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study.
    Kim J, Yoon H, Kim N, et al. · Inflamm Bowel Dis · 2022 · Background
    PubMed: PMID 33501935 · NCT05186623 · Colitis, Ulcerative
  35. Ustekinumab dose escalation improves clinical responses in refractory Crohn's disease.
    Haider SA, Yadav A, Perry C, et al. · Ther Adv Gastroenterol · 2022 · Background
    PubMed: PMID 33133239 · NCT06520397 · Crohn Disease
  36. Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles.
    Fuchs F, Schillinger D, Atreya R, et al. · Front Immunol · 2022 · Background
    PubMed: PMID 28717358 · NCT03885713 (BioIBD) · Crohn Disease
  37. Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
    Bermejo F, Jiménez L, Algaba A, et al. · Inflamm Bowel Dis · 2022 · Background
    PubMed: PMID 33528018 · NCT06520397 · Crohn Disease
  38. Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases.
    Alayo QA, Khatiwada A, Patel A, et al. · Inflamm Bowel Dis · 2022 · Background
    PubMed: PMID 34037225 · NCT06520397 · Crohn Disease

2021 (25 papers)

  1. Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S).
    Wasel N, Thaçi D, French LE, et al. · Dermatol Ther (Heidelb) · 2021 · Derived
    PubMed: PMID 32415575 · NCT02561806 (IXORA-S)
  2. Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis.
    Suleiman AA, Khatri A, Oberoi RK, et al. · Clin Pharmacokinet · 2021 · Derived
    PubMed: PMID 31667790 · NCT02054481 · Psoriasis
  3. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Reich K, Papp KA, Blauvelt A, et al. · Lancet · 2021 · Derived
    PubMed: PMID 33549193 · NCT03370133 (BE VIVID) · Psoriasis
  4. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
    Panaccione R, Danese S, Sandborn WJ, et al. · Aliment Pharmacol Ther · 2021 · Derived
    PubMed: PMID 33086438 · NCT02407236 (UNIFI) · Colitis, Ulcerative
  5. Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.
    Mease PJ, Gladman DD, Deodhar A, et al. · RMD Open · 2021 · Derived
    PubMed: PMID 32665433 · NCT02319759 · Arthritis, Psoriatic
  6. Ustekinumab for the Treatment of Giant Cell Arteritis.
    Matza MA, Fernandes AD, Stone JH, et al. · Arthritis Care Res (Hoboken) · 2021 · Derived
    PubMed: PMID 32248659 · NCT02955147 (UGCA) · Giant Cell Arteritis
  7. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis.
    Li K, Marano C, Zhang H, et al. · Gastroenterology · 2021 · Derived
    PubMed: PMID 32853634 · NCT02407236 (UNIFI) · Colitis, Ulcerative
  8. Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors.
    Kokolakis G, Vadstrup K, Hansen JB, et al. · Dermatol Ther (Heidelb) · 2021 · Derived
    PubMed: PMID 34606048 · NCT01708629 (AMAGINE-3) · Psoriasis
  9. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.
    Helliwell PS, Gladman DD, Chakravarty SD, et al. · RMD Open · 2021 · Derived
    PubMed: PMID 32209721 · NCT01077362 · Psoriasis
  10. Interventions for cutaneous disease in systemic lupus erythematosus.
    Hannon CW, McCourt C, Lima HC, et al. · Cochrane Database Syst Rev · 2021 · Derived
    PubMed: PMID 33687069 · NCT03517722 · Lupus Erythematosus, Systemic
  11. Malignancy Rates in Brodalumab Clinical Studies for Psoriasis.
    Gottlieb A, Lebwohl M, Liu C, et al. · Am J Clin Dermatol · 2021 · Derived
    PubMed: PMID 32207067 · NCT01708603 (AMAGINE-2) · Psoriasis
  12. Treatment strategies for glucose-6-phosphate dehydrogenase deficiency: past and future perspectives.
    Garcia AA, Koperniku A, Ferreira JCB, et al. · Trends Pharmacol Sci · 2021 · Derived
    PubMed: PMID 34389161 · NCT03167437 · Crohn Disease
  13. Suppression of Serum Interferon-γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus.
    Cesaroni M, Seridi L, Loza MJ, et al. · Arthritis Rheumatol · 2021 · Derived
    PubMed: PMID 33010188 · NCT02349061 · Lupus Erythematosus, Systemic
  14. Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY).
    Bagel J, Blauvelt A, Nia J, et al. · J Eur Acad Dermatol Venereol · 2021 · Derived
    PubMed: PMID 32365251 · NCT02826603 (CLARITY)
  15. Continued treatment with secukinumab is associated with high retention or regain of response.
    Augustin M, Thaci D, Eyerich K, et al. · Br J Dermatol · 2021 · Derived
    PubMed: PMID 30972746 · NCT02074982 · Dermatitis
  16. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
    Augustin M, Lambert J, Zema C, et al. · JAMA Dermatol · 2021 · Derived
    PubMed: PMID 33052382 · NCT02684357 · Psoriasis
  17. Geographical Variation and Factors Associated With Inflammatory Bowel Disease in a Central Canadian Province.
    Torabi M, Bernstein CN, Yu BN, et al. · Inflamm Bowel Dis · 2021 · Background
    PubMed: PMID 31504519 · NCT05386290 · Crohn Disease
  18. Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease.
    Schultheiss JPD, Mahmoud R, Louwers JM, et al. · Aliment Pharmacol Ther · 2021 · Background
    PubMed: PMID 34559428 · NCT06520397 · Crohn Disease
  19. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches.
    Privitera G, Pugliese D, Lopetuso LR, et al. · Ther Adv Gastroenterol · 2021 · Background
    PubMed: PMID 33995579 · NCT06520397 · Crohn Disease
  20. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease.
    Ollech JE, Normatov I, Peleg N, et al. · Clin Gastroenterol Hepatol · 2021 · Background
    PubMed: PMID 32109634 · NCT06520397 · Crohn Disease
  21. Increasing newly diagnosed inflammatory bowel disease and improving prognosis in China: a 30-year retrospective study from a single centre.
    Lv H, Jin M, Zhang H, et al. · BMC Gastroenterol · 2021 · Background
    PubMed: PMID 33183228 · NCT05386290 · Crohn Disease
  22. Efficacy and Safety of Dual Biologic Therapy in Patients With Inflammatory Bowel Disease: A Review of the Literature.
    Gold SL, Steinlauf AF · Gastroenterol Hepatol (N Y) · 2021 · Background
    PubMed: PMID 34602905 · NCT06520397 · Crohn Disease
  23. Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium.
    Fenster M, Alayo QA, Khatiwada A, et al. · Clin Gastroenterol Hepatol · 2021 · Background
    PubMed: PMID 33068786 · NCT06520397 · Crohn Disease
  24. Large-scale pathway specific polygenic risk and transcriptomic community network analysis identifies novel functional pathways in Parkinson disease.
    Bandres-Ciga S, Saez-Atienzar S, Kim JJ, et al. · Acta Neuropathol · 2021 · Background
    PubMed: PMID 32601912 · NCT05186623 · Colitis, Ulcerative
  25. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
    Alulis S, Vadstrup K, Borsi A, et al. · Scand J Gastroenterol · 2021 · Background
    PubMed: PMID 32116064 · NCT07495644 · Crohn Disease

2020 (13 papers)

  1. Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus.
    van Vollenhoven RF, Hahn BH, Tsokos GC, et al. · Arthritis Rheumatol · 2020 · Derived
    PubMed: PMID 31769212 · NCT02349061 · Lupus Erythematosus, Systemic
  2. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials.
    Suleiman AA, Minocha M, Khatri A, et al. · Clin Pharmacokinet · 2020 · Derived
    PubMed: PMID 31054118 · NCT02684357 · Psoriasis
  3. Responsiveness of Serum C-Reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-Blind, Placebo-Controlled Trials.
    Siebert S, Sweet K, Dasgupta B, et al. · Arthritis Rheumatol · 2020 · Derived
    PubMed: PMID 31070869 · NCT01009086 · Psoriasis
  4. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
    Langley RG, Armstrong AW, Lebwohl MG, et al. · Br J Dermatol · 2020 · Derived
    PubMed: PMID 30328108 · NCT01708603 (AMAGINE-2) · Psoriasis
  5. Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial.
    Helliwell PS, Deodhar A, Gottlieb AB, et al. · Arthritis Care Res (Hoboken) · 2020 · Derived
    PubMed: PMID 31421033 · NCT02319759 · Arthritis, Psoriatic
  6. IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
    Hanauer SB, Sandborn WJ, Feagan BG, et al. · J Crohns Colitis · 2020 · Derived
    PubMed: PMID 31158271 · NCT01369355 · Crohn Disease
  7. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs.
    Ghosh S, Gensler LS, Yang Z, et al. · Drug Saf · 2020 · Derived
    PubMed: PMID 30739254 · NCT01369355 · Crohn Disease
  8. Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results).
    Bagel J, Nia J, Hashim PW, et al. · Dermatol Ther (Heidelb) · 2020 · Derived
    PubMed: PMID 30334147 · NCT02826603 (CLARITY)
  9. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
    Yang E, Panaccione N, Whitmire N, et al. · Aliment Pharmacol Ther · 2020 · Background
    PubMed: PMID 32329532 · NCT06520397 · Crohn Disease
  10. Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing.
    Schleier L, Wiendl M, Heidbreder K, et al. · Gut · 2020 · Background
    PubMed: PMID 31092589 · NCT05186623 · Colitis, Ulcerative
  11. Pharmacological enrichment of polygenic risk for precision medicine in complex disorders.
    Reay WR, Atkins JR, Carr VJ, et al. · Sci Rep · 2020 · Background
    PubMed: PMID 31964963 · NCT05186623 · Colitis, Ulcerative
  12. A 30-year Trend Analysis in the Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District of Seoul, Korea in 1986-2015.
    Park SH, Kim YJ, Rhee KH, et al. · J Crohns Colitis · 2020 · Background
    PubMed: PMID 30989166 · NCT05186623 · Colitis, Ulcerative
  13. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    GBD 2017 Inflammatory Bowel Disease Collaborators · Lancet Gastroenterol Hepatol · 2020 · Background
    PubMed: PMID 31648971 · NCT07495644 · Crohn Disease

2019 (16 papers)

  1. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sands BE, Sandborn WJ, Panaccione R, et al. · N Engl J Med · 2019 · Derived
    PubMed: PMID 31553833 · NCT02407236 (UNIFI) · Colitis, Ulcerative
  2. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
    Sandborn WJ, Rutgeerts P, Gasink C, et al. · Aliment Pharmacol Ther · 2019 · Derived
    PubMed: PMID 29797519 · NCT01369355 · Crohn Disease
  3. In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation.
    Pidala J, Beato F, Kim J, et al. · Haematologica · 2019 · Derived
    PubMed: PMID 29242294 · NCT01713400 (Ustekinumab) · Graft vs Host Disease
  4. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.
    McMichael A, Desai SR, Qureshi A, et al. · Am J Clin Dermatol · 2019 · Derived
    PubMed: PMID 30471012 · NCT01708629 (AMAGINE-3) · Psoriasis
  5. Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial.
    Loesche MA, Farahi K, Capone K, et al. · J Invest Dermatol · 2019 · Derived
    PubMed: PMID 29559344 · NCT01550744 (PSTELLAR) · Psoriasis
  6. Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.
    Li K, Friedman JR, Chan D, et al. · Gastroenterology · 2019 · Derived
    PubMed: PMID 31279870 · NCT01369355 · Crohn Disease
  7. Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.
    Deodhar A, Gensler LS, Sieper J, et al. · Arthritis Rheumatol · 2019 · Derived
    PubMed: PMID 30225992 · NCT02437162 · Axial Spondyloarthritis
  8. Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR).
    Blauvelt A, Ferris LK, Yamauchi PS, et al. · Br J Dermatol · 2019 · Derived
    PubMed: PMID 28600818 · NCT01550744 (PSTELLAR) · Psoriasis
  9. Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals.
    Uzzan M, Tokuyama M, Rosenstein AK, et al. · Sci Transl Med · 2019 · Background
    PubMed: PMID 30282696 · NCT05186623 · Colitis, Ulcerative
  10. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
    Ungar B, Kopylov U, Yavzori M, et al. · Clin Gastroenterol Hepatol · 2019 · Background
    PubMed: PMID 29223444 · NCT05186623 · Colitis, Ulcerative
  11. Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease.
    Stikvoort A, Chen Y, Rådestad E, et al. · Front Immunol · 2019 · Background
    PubMed: PMID 28674539 · NCT03885713 (BioIBD) · Crohn Disease
  12. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
    Sands BE, Peyrin-Biroulet L, Loftus EV, et al. · N Engl J Med · 2019 · Background
    PubMed: PMID 31553834 · NCT05186623 · Colitis, Ulcerative
  13. Population Density and Risk of Inflammatory Bowel Disease: A Prospective Population-Based Study in 13 Countries or Regions in Asia-Pacific.
    Ng SC, Kaplan GG, Tang W, et al. · Am J Gastroenterol · 2019 · Background
    PubMed: PMID 30177785 · NCT05386290 · Crohn Disease
  14. Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review.
    Jean L, Audrey M, Beauchemin C, et al. · Can J Gastroenterol Hepatol · 2019 · Background
    PubMed: PMID 30009158 · NCT05386290 · Crohn Disease
  15. A blood-based prognostic biomarker in IBD.
    Biasci D, Lee JC, Noor NM, et al. · Gut · 2019 · Background
    PubMed: PMID 31030191 · NCT05186623 · Colitis, Ulcerative
  16. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
    Barré A, Colombel JF, Ungaro R, et al. · Aliment Pharmacol Ther · 2019 · Background
    PubMed: PMID 29430672 · NCT05186623 · Colitis, Ulcerative

2018 (19 papers)

  1. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis.
    Conrad C, Di Domizio J, Mylonas A, et al. · Nat Commun · 2018 · Trial result
    PubMed: PMID 29295985 · NCT03629379 (STRAUSS) · Psoriasis
  2. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
    van Vollenhoven RF, Hahn BH, Tsokos GC, et al. · Lancet · 2018 · Derived
    PubMed: PMID 30249507 · NCT02349061 · Lupus Erythematosus, Systemic
  3. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
    Rutgeerts P, Gasink C, Chan D, et al. · Gastroenterology · 2018 · Derived
    PubMed: PMID 29909019 · NCT01369342 · Crohn Disease
  4. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB, Strober B, Lebwohl M, et al. · Lancet · 2018 · Derived
    PubMed: PMID 30097359 · NCT02684357 · Psoriasis
  5. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
    Deodhar A, Gottlieb AB, Boehncke WH, et al. · Lancet · 2018 · Derived
    PubMed: PMID 29893222 · NCT02319759 · Arthritis, Psoriatic
  6. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
    Adedokun OJ, Xu Z, Gasink C, et al. · Gastroenterology · 2018 · Derived
    PubMed: PMID 29409871 · NCT01369342 · Crohn Disease
  7. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
    Zeissig S, Rosati E, Dowds CM, et al. · Gut · 2018 · Background
    PubMed: PMID 29730603 · NCT05186623 · Colitis, Ulcerative
  8. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
    Singh S, George J, Boland BS, et al. · J Crohns Colitis · 2018 · Background
    PubMed: PMID 29370397 · NCT06520397 · Crohn Disease
  9. Endoscopy in inflammatory bowel disease: advances in disease management.
    Scoville EA, Schwartz DA · Gastrointest Endosc · 2018 · Background
    PubMed: PMID 28886962 · NCT03885713 (BioIBD) · Crohn Disease
  10. Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis.
    Planell N, Masamunt MC, Leal RF, et al. · J Crohns Colitis · 2018 · Background
    PubMed: PMID 28981629 · NCT03885713 (BioIBD) · Crohn Disease
  11. Advances in the use of biologics and other novel drugs for managing inflammatory bowel disease.
    Park SH, Aniwan S, Loftus EV, et al. · Curr Opin Pharmacol · 2018 · Background
    PubMed: PMID 28992449 · NCT03885713 (BioIBD) · Crohn Disease
  12. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.
    Ng SC, Shi HY, Hamidi N, et al. · Lancet · 2018 · Background
    PubMed: PMID 29050646 · NCT03885713 (BioIBD) · Crohn Disease
  13. Can We Predict the Efficacy of Anti-TNF-α Agents?
    Lopetuso LR, Gerardi V, Papa V, et al. · Int J Mol Sci · 2018 · Background
    PubMed: PMID 28906475 · NCT03885713 (BioIBD) · Crohn Disease
  14. The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?
    Hindryckx P, Vande Casteele N, Novak G, et al. · J Crohns Colitis · 2018 · Background
    PubMed: PMID 28961959 · NCT03885713 (BioIBD) · Crohn Disease
  15. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.
    Hassan EA, Ramadan HK, Ismael AA, et al. · Saudi J Gastroenterol · 2018 · Background
    PubMed: PMID 28721978 · NCT03885713 (BioIBD) · Crohn Disease
  16. Ustekinumab to treat Crohn's disease.
    Gisbert JP, Chaparro M · Gastroenterol Hepatol · 2018 · Background
    PubMed: PMID 29042094 · NCT03885713 (BioIBD) · Crohn Disease
  17. Serum Interleukin 9 Levels Predict Disease Severity and the Clinical Efficacy of Infliximab in Patients with Crohn's Disease.
    Feng T, Chen B, Li L, et al. · Inflamm Bowel Dis · 2018 · Background
    PubMed: PMID 28644181 · NCT03885713 (BioIBD) · Crohn Disease
  18. Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
    Dulai PS, Boland BS, Singh S, et al. · Gastroenterology · 2018 · Background
    PubMed: PMID 29857091 · NCT05186623 · Colitis, Ulcerative
  19. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
    Domènech E, Gisbert JP · Gastroenterol Hepatol · 2018 · Background
    PubMed: PMID 26948838 · NCT03885713 (BioIBD) · Crohn Disease

2017 (17 papers)

  1. A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate.
    Smolen JS, Agarwal SK, Ilivanova E, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 28087506 · NCT01645280 · Arthritis, Rheumatoid
  2. Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis.
    Rahman P, Puig L, Gottlieb AB, et al. · Arthritis Care Res (Hoboken) · 2017 · Derived
    PubMed: PMID 27483458 · NCT01009086 · Psoriasis
  3. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
    Papp KA, Blauvelt A, Bukhalo M, et al. · N Engl J Med · 2017 · Derived
    PubMed: PMID 28423301 · NCT02054481 · Psoriasis
  4. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2).
    Kavanaugh A, Puig L, Gottlieb AB, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 27098404 · NCT01009086 · Psoriasis
  5. Lowering Interleukin-12 Activity Improves Myocardial and Vascular Function Compared With Tumor Necrosis Factor-a Antagonism or Cyclosporine in Psoriasis.
    Ikonomidis I, Papadavid E, Makavos G, et al. · Circ Cardiovasc Imaging · 2017 · Derived
    PubMed: PMID 28899951 · NCT02144857 · Psoriasis
  6. High-Throughput Characterization of Blood Serum Proteomics of IBD Patients with Respect to Aging and Genetic Factors.
    Di Narzo AF, Telesco SE, Brodmerkel C, et al. · PLoS Genet · 2017 · Derived
    PubMed: PMID 28129359 · NCT00771667 · Crohn Disease
  7. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials.
    Vuitton L, Marteau P, Sandborn WJ, et al. · Gut · 2017 · Background
    PubMed: PMID 26353983 · NCT03885713 (BioIBD) · Crohn Disease
  8. Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF.
    Viazis N, Giakoumis M, Bamias G, et al. · Dig Liver Dis · 2017 · Background
    PubMed: PMID 27866814 · NCT03885713 (BioIBD) · Crohn Disease
  9. Mass Cytometry of the Human Mucosal Immune System Identifies Tissue- and Disease-Associated Immune Subsets.
    van Unen V, Li N, Molendijk I, et al. · Immunity · 2017 · Background
    PubMed: PMID 27178470 · NCT03885713 (BioIBD) · Crohn Disease
  10. Mass Cytometry: Single Cells, Many Features.
    Spitzer MH, Nolan GP · Cell · 2017 · Background
    PubMed: PMID 27153492 · NCT03885713 (BioIBD) · Crohn Disease
  11. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sandborn WJ, Su C, Sands BE, et al. · N Engl J Med · 2017 · Background
    PubMed: PMID 28467869 · NCT05186623 · Colitis, Ulcerative
  12. Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease.
    Pineton de Chambrun G, Blanc P, Peyrin-Biroulet L, et al. · Expert Rev Gastroenterol Hepatol · 2017 · Background
    PubMed: PMID 27043489 · NCT03885713 (BioIBD) · Crohn Disease
  13. A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease.
    Pillai N, Dusheiko M, Burnand B, et al. · PLoS One · 2017 · Background
    PubMed: PMID 28973005 · NCT05386290 · Crohn Disease
  14. The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
    Gisbert JP, Marín AC, Chaparro M, et al. · Am J Gastroenterol · 2017 · Background
    PubMed: PMID 27002797 · NCT03885713 (BioIBD) · Crohn Disease
  15. Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a 'European ADNI study'.
    Galluzzi S, Marizzoni M, Babiloni C, et al. · J Intern Med · 2017 · Background
    PubMed: PMID 26940242 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  16. Targeting neuroinflammation in Alzheimer's disease: evidence for NSAIDs and novel therapeutics.
    Deardorff WJ, Grossberg GT · Expert Rev Neurother · 2017 · Background
    PubMed: PMID 27293026 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  17. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.
    Arbelaiz A, Azkargorta M, Krawczyk M, et al. · Hepatology · 2017 · Background
    PubMed: PMID 28555885 · NCT03885713 (BioIBD) · Crohn Disease

2016 (19 papers)

  1. Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study.
    Cleynen I, Van Moerkercke W, Billiet T, et al. · Ann Intern Med · 2016 · Trial result
    PubMed: PMID 26641955 · NCT03629379 (STRAUSS) · Psoriasis
  2. Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial.
    Kavanaugh A, Puig L, Gottlieb AB, et al. · Arthritis Care Res (Hoboken) · 2016 · Derived
    PubMed: PMID 26097039 · NCT01009086 · Psoriasis
  3. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
    Feagan BG, Sandborn WJ, Gasink C, et al. · N Engl J Med · 2016 · Derived
    PubMed: PMID 27959607 · NCT01369355 · Crohn Disease
  4. The Biomarkers for Identifying Preclinical Alzheimer's Disease via Structural and Functional Magnetic Resonance Imaging.
    Zhou Y, Tan C, Wen D, et al. · Front Aging Neurosci · 2016 · Background
    PubMed: PMID 27199739 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  5. Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.
    Tew GW, Hackney JA, Gibbons D, et al. · Gastroenterology · 2016 · Background
    PubMed: PMID 26522261 · NCT03885713 (BioIBD) · Crohn Disease
  6. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease.
    Shah SC, Colombel JF, Sands BE, et al. · Aliment Pharmacol Ther · 2016 · Background
    PubMed: PMID 26607562 · NCT03885713 (BioIBD) · Crohn Disease
  7. Health Care Cost Analysis in a Population-based Inception Cohort of Inflammatory Bowel Disease Patients in the First Year of Diagnosis.
    Niewiadomski O, Studd C, Hair C, et al. · J Crohns Colitis · 2016 · Background
    PubMed: PMID 26129692 · NCT03885713 (BioIBD) · Crohn Disease
  8. Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy.
    Nair N, Mei HE, Chen SY, et al. · Arthritis Res Ther · 2016 · Background
    PubMed: PMID 25981462 · NCT03885713 (BioIBD) · Crohn Disease
  9. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease.
    Kopylov U, Seidman E · Ther Adv Gastroenterol · 2016 · Background
    PubMed: PMID 27366220 · NCT03885713 (BioIBD) · Crohn Disease
  10. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.
    Jonas O, Landry HM, Fuller JE, et al. · Sci Transl Med · 2016 · Background
    PubMed: PMID 25904741 · NCT07352566 · Psoriasis
  11. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis.
    Jin Y, Lin Y, Lin LJ, et al. · World J Gastroenterol · 2016 · Background
    PubMed: PMID 26034371 · NCT07495644 · Crohn Disease
  12. Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease.
    Gurney ME, D'Amato EC, Burgin AB, et al. · Neurotherapeutics · 2016 · Background
    PubMed: PMID 25371167 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  13. A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease.
    Green RC, Christensen KD, Cupples LA, et al. · Alzheimers Dement · 2016 · Background
    PubMed: PMID 25499536 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  14. Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys.
    Gordon JP, McEwan PC, Maguire A, et al. · Eur J Gastroenterol Hepatol · 2016 · Background
    PubMed: PMID 25933126 · NCT03885713 (BioIBD) · Crohn Disease
  15. [Vedolizumab in the treatment of Crohn's disease].
    Gisbert JP, Domènech E · Gastroenterol Hepatol · 2016 · Background
    PubMed: PMID 25619903 · NCT03885713 (BioIBD) · Crohn Disease
  16. Clinical recovery from surgery correlates with single-cell immune signatures.
    Gaudillière B, Fragiadakis GK, Bruggner RV, et al. · Sci Transl Med · 2016 · Background
    PubMed: PMID 25253674 · NCT03885713 (BioIBD) · Crohn Disease
  17. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.
    Ding NS, Hart A, De Cruz P, et al. · Aliment Pharmacol Ther · 2016 · Background
    PubMed: PMID 26515897 · NCT03885713 (BioIBD) · Crohn Disease
  18. Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy.
    Dahlén R, Magnusson MK, Bajor A, et al. · Scand J Gastroenterol · 2016 · Background
    PubMed: PMID 25877762 · NCT03885713 (BioIBD) · Crohn Disease
  19. Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial.
    Christensen KD, Roberts JS, Whitehouse PJ, et al. · Ann Intern Med · 2016 · Background
    PubMed: PMID 26810768 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease

2015 (16 papers)

  1. An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17.
    Grine L, Dejager L, Libert C, et al. · Cytokine Growth Factor Rev · 2015 · Trial result
    PubMed: PMID 25434285 · NCT03629379 (STRAUSS) · Psoriasis
  2. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D, Blauvelt A, Reich K, et al. · J Am Acad Dermatol · 2015 · Derived
    PubMed: PMID 26092291 · NCT02074982 · Dermatitis
  3. Advances in pharmacotherapy for primary biliary cirrhosis.
    Mousa HS, Lleo A, Invernizzi P, et al. · Expert Opin Pharmacother · 2015 · Derived
    PubMed: PMID 25543678 · NCT01389973 · Liver Cirrhosis, Biliary
  4. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
    Lebwohl M, Strober B, Menter A, et al. · N Engl J Med · 2015 · Derived
    PubMed: PMID 26422722 · NCT01708603 (AMAGINE-2) · Psoriasis
  5. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.
    Landells I, Marano C, Hsu MC, et al. · J Am Acad Dermatol · 2015 · Derived
    PubMed: PMID 26259989 · NCT01090427 · Psoriasis
  6. Validation and important differences for the Sarcoidosis Assessment Tool. A new patient-reported outcome measure.
    Judson MA, Mack M, Beaumont JL, et al. · Am J Respir Crit Care Med · 2015 · Derived
    PubMed: PMID 25594886 · NCT00955279 · Sarcoidosis
  7. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.
    Judson MA, Baughman RP, Costabel U, et al. · Eur Respir J · 2015 · Derived
    PubMed: PMID 25034562 · NCT00955279 · Sarcoidosis
  8. Anti-TNF therapeutics for the treatment of sarcoidosis.
    Crommelin HA, Vorselaars AD, van Moorsel CH, et al. · Immunotherapy · 2015 · Derived
    PubMed: PMID 25428650 · NCT00955279 · Sarcoidosis
  9. Arterial spin labeling may contribute to the prediction of cognitive deterioration in healthy elderly individuals.
    Xekardaki A, Rodriguez C, Montandon ML, et al. · Radiology · 2015 · Background
    PubMed: PMID 25291458 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  10. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
    Peyrin-Biroulet L, Sandborn W, Sands BE, et al. · Am J Gastroenterol · 2015 · Background
    PubMed: PMID 26303131 · NCT03885713 (BioIBD) · Crohn Disease
  11. A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design.
    Khanna R, Bouguen G, Feagan BG, et al. · Inflamm Bowel Dis · 2015 · Background
    PubMed: PMID 25029615 · NCT03885713 (BioIBD) · Crohn Disease
  12. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview.
    Heckman PR, Wouters C, Prickaerts J, et al. · Curr Pharm Des · 2015 · Background
    PubMed: PMID 25159073 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  13. Towards personalized care in IBD.
    Gerich ME, McGovern DP · Nat Rev Gastroenterol Hepatol · 2015 · Background
    PubMed: PMID 24345887 · NCT03885713 (BioIBD) · Crohn Disease
  14. CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages.
    Fergusson JR, Smith KE, Fleming VM, et al. · Cell Rep · 2015 · Background
    PubMed: PMID 25437561 · NCT03885713 (BioIBD) · Crohn Disease
  15. Physiological intermolecular modification spectroscopy for the prediction of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel diseases.
    Eftekhari P, Glaubitz L, Breidert M, et al. · Dig Dis · 2015 · Background
    PubMed: PMID 24969293 · NCT03885713 (BioIBD) · Crohn Disease
  16. Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans.
    Choi SW, Gatza E, Hou G, et al. · Blood · 2015 · Background
    PubMed: PMID 25428224 · NCT03167437 · Crohn Disease

2014 (12 papers)

  1. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.
    Tillack C, Ehmann LM, Friedrich M, et al. · Gut · 2014 · Trial result
    PubMed: PMID 23468464 · NCT03629379 (STRAUSS) · Psoriasis
  2. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).
    Poddubnyy D, Hermann KG, Callhoff J, et al. · Ann Rheum Dis · 2014 · Derived
    PubMed: PMID 24389297 · NCT01330901 (TOPAS) · Spondylitis, Ankylosing
  3. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease.
    Stidham RW, Lee TC, Higgins PD, et al. · Aliment Pharmacol Ther · 2014 · Background
    PubMed: PMID 24749763 · NCT03885713 (BioIBD) · Crohn Disease
  4. Proteomic patterns of colonic mucosal tissues delineate Crohn's colitis and ulcerative colitis.
    Seeley EH, Washington MK, Caprioli RM, et al. · Proteomics Clin Appl · 2014 · Background
    PubMed: PMID 23382084 · NCT03885713 (BioIBD) · Crohn Disease
  5. Early indications of future cognitive decline: stable versus declining controls.
    Rizk-Jackson A, Insel P, Petersen R, et al. · PLoS One · 2014 · Background
    PubMed: PMID 24040166 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  6. Preventing cognitive decline in preclinical Alzheimer's disease.
    Riedel WJ · Curr Opin Pharmacol · 2014 · Background
    PubMed: PMID 24565007 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  7. A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease.
    Peters KR, Lynn Beattie B, Feldman HH, et al. · Prog Neurobiol · 2014 · Background
    PubMed: PMID 23348495 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  8. Cytokines in inflammatory bowel disease.
    Neurath MF · Nat Rev Immunol · 2014 · Background
    PubMed: PMID 24751956 · NCT07495644 · Crohn Disease
  9. Inflammatory bowel disease: an expanding global health problem.
    M'Koma AE · Clin Med Insights Gastroenterol · 2014 · Background
    PubMed: PMID 24833941 · NCT03885713 (BioIBD) · Crohn Disease
  10. Ushering in the study and treatment of preclinical Alzheimer disease.
    Langbaum JB, Fleisher AS, Chen K, et al. · Nat Rev Neurol · 2014 · Background
    PubMed: PMID 23752908 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  11. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.
    Choi SW, Braun T, Chang L, et al. · Lancet Oncol · 2014 · Background
    PubMed: PMID 24295572 · NCT03167437 · Crohn Disease
  12. Emerging therapeutics for Alzheimer's disease.
    Chiang K, Koo EH · Annu Rev Pharmacol Toxicol · 2014 · Background
    PubMed: PMID 24392696 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease

2013 (12 papers)

  1. Paradoxical inflammation induced by anti-TNF agents in patients with IBD.
    Cleynen I, Vermeire S · Nat Rev Gastroenterol Hepatol · 2013 · Trial result
    PubMed: PMID 22751454 · NCT03629379 (STRAUSS) · Psoriasis
  2. Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studies.
    Zhu Y, Wang Q, Frederick B, et al. · Clin Drug Investig · 2013 · Derived
    PubMed: PMID 23512638 · NCT01081704
  3. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
    McInnes IB, Kavanaugh A, Gottlieb AB, et al. · Lancet · 2013 · Derived
    PubMed: PMID 23769296 · NCT01009086 · Psoriasis
  4. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline.
    Vom Berg J, Prokop S, Miller KR, et al. · Nat Med · 2013 · Background
    PubMed: PMID 23178247 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  5. Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals.
    Lazarczyk MJ, Hof PR, Bouras C, et al. · BMC Med · 2013 · Background
    PubMed: PMID 23098093 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  6. Label-free quantification for discovering novel biomarkers in the diagnosis and assessment of disease activity in inflammatory bowel disease.
    Han NY, Choi W, Park JM, et al. · J Dig Dis · 2013 · Background
    PubMed: PMID 23320753 · NCT03885713 (BioIBD) · Crohn Disease
  7. Neuroinflammatory cytokine signaling and Alzheimer's disease.
    Griffin WS · N Engl J Med · 2013 · Background
    PubMed: PMID 23425171 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  8. Phosphodiesterases as therapeutic targets for Alzheimer's disease.
    García-Osta A, Cuadrado-Tejedor M, García-Barroso C, et al. · ACS Chem Neurosci · 2013 · Background
    PubMed: PMID 23173065 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  9. Vedolizumab as induction and maintenance therapy for ulcerative colitis.
    Feagan BG, Rutgeerts P, Sands BE, et al. · N Engl J Med · 2013 · Background
    PubMed: PMID 23964932 · NCT05186623 · Colitis, Ulcerative
  10. Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease.
    D'Haens G, Feagan B, Colombel JF, et al. · Gastroenterology · 2013 · Background
    PubMed: PMID 23000597 · NCT03885713 (BioIBD) · Crohn Disease
  11. The potential protective effect of tramiprosate (homotaurine) against Alzheimer's disease: a review.
    Caltagirone C, Ferrannini L, Marchionni N, et al. · Aging Clin Exp Res · 2013 · Background
    PubMed: PMID 22961121 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  12. Assessment of Alzheimer's disease risk with functional magnetic resonance imaging: an arterial spin labeling study.
    Bangen KJ, Restom K, Liu TT, et al. · J Alzheimers Dis · 2013 · Background
    PubMed: PMID 22531427 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease

2012 (10 papers)

  1. Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
    Sandborn WJ, Gasink C, Gao LL, et al. · N Engl J Med · 2012 · Derived
    PubMed: PMID 23075178 · NCT00771667 · Crohn Disease
  2. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis.
    Rismo R, Olsen T, Cui G, et al. · Scand J Gastroenterol · 2012 · Background
    PubMed: PMID 22486187 · NCT03885713 (BioIBD) · Crohn Disease
  3. Results of the 2nd scientific workshop of the ECCO (III): basic mechanisms of intestinal healing.
    Rieder F, Karrasch T, Ben-Horin S, et al. · J Crohns Colitis · 2012 · Background
    PubMed: PMID 22405177 · NCT03885713 (BioIBD) · Crohn Disease
  4. Host-microbe relationships in inflammatory bowel disease detected by bacterial and metaproteomic analysis of the mucosal-luminal interface.
    Presley LL, Ye J, Li X, et al. · Inflamm Bowel Dis · 2012 · Background
    PubMed: PMID 21698720 · NCT03885713 (BioIBD) · Crohn Disease
  5. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease.
    Peyrin-Biroulet L, Ferrante M, Magro F, et al. · J Crohns Colitis · 2012 · Background
    PubMed: PMID 21939925 · NCT03885713 (BioIBD) · Crohn Disease
  6. Inflammatory bowel disease in the 21(st) century in China: turning challenges into opportunities.
    Ouyang Q, Xue LY · J Dig Dis · 2012 · Background
    PubMed: PMID 22435503 · NCT05386290 · Crohn Disease
  7. Mucosal healing in inflammatory bowel diseases: a systematic review.
    Neurath MF, Travis SP · Gut · 2012 · Background
    PubMed: PMID 22842618 · NCT03885713 (BioIBD) · Crohn Disease
  8. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.
    Molodecky NA, Soon IS, Rabi DM, et al. · Gastroenterology · 2012 · Background
    PubMed: PMID 22001864 · NCT05186623 · Colitis, Ulcerative
  9. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting.
    Gelfand JM, Wan J, Callis Duffin K, et al. · Arch Dermatol · 2012 · Background
    PubMed: PMID 22508874 · NCT02330380 · Psoriasis
  10. A deep profiler's guide to cytometry.
    Bendall SC, Nolan GP, Roederer M, et al. · Trends Immunol · 2012 · Background
    PubMed: PMID 22476049 · NCT03885713 (BioIBD) · Crohn Disease

2011 (13 papers)

  1. Prediction of cognitive decline in healthy older adults using fMRI.
    Woodard JL, Seidenberg M, Nielson KA, et al. · J Alzheimers Dis · 2011 · Background
    PubMed: PMID 20634590 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  2. Predicting response to Anti-TNF Agents for the treatment of crohn's disease.
    Siegel CA, Melmed GY · Ther Adv Gastroenterol · 2011 · Background
    PubMed: PMID 21180547 · NCT03885713 (BioIBD) · Crohn Disease
  3. Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study.
    Nunes T, Barreiro-de Acosta M, Nos P, et al. · J Crohns Colitis · 2011 · Background
    PubMed: PMID 21122572 · NCT03885713 (BioIBD) · Crohn Disease
  4. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study.
    Mehta NN, Yu Y, Saboury B, et al. · Arch Dermatol · 2011 · Background
    PubMed: PMID 21576552 · NCT02330380 · Psoriasis
  5. Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides.
    M'Koma AE, Seeley EH, Washington MK, et al. · Inflamm Bowel Dis · 2011 · Background
    PubMed: PMID 20806340 · NCT03885713 (BioIBD) · Crohn Disease
  6. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis.
    Lee JC, Lyons PA, McKinney EF, et al. · J Clin Invest · 2011 · Background
    PubMed: PMID 21946256 · NCT05186623 · Colitis, Ulcerative
  7. Individual prediction of cognitive decline in mild cognitive impairment using support vector machine-based analysis of diffusion tensor imaging data.
    Haller S, Nguyen D, Rodriguez C, et al. · J Alzheimers Dis · 2011 · Background
    PubMed: PMID 20847435 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  8. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.
    Ford AC, Sandborn WJ, Khan KJ, et al. · Am J Gastroenterol · 2011 · Background
    PubMed: PMID 21407183 · NCT03885713 (BioIBD) · Crohn Disease
  9. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer.
    Dinarello CA, Fossati G, Mascagni P, et al. · Mol Med · 2011 · Background
    PubMed: PMID 21556484 · NCT03167437 · Crohn Disease
  10. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
    D'Haens GR, Panaccione R, Higgins PD, et al. · Am J Gastroenterol · 2011 · Background
    PubMed: PMID 21045814 · NCT03885713 (BioIBD) · Crohn Disease
  11. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
    Colombel JF, Rutgeerts P, Reinisch W, et al. · Gastroenterology · 2011 · Background
    PubMed: PMID 21723220 · NCT03885713 (BioIBD) · Crohn Disease
  12. Local MRI analysis approach in the diagnosis of early and prodromal Alzheimer's disease.
    Chincarini A, Bosco P, Calvini P, et al. · Neuroimage · 2011 · Background
    PubMed: PMID 21718788 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  13. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease.
    Arijs I, Quintens R, Van Lommel L, et al. · Inflamm Bowel Dis · 2011 · Background
    PubMed: PMID 20848504 · NCT03885713 (BioIBD) · Crohn Disease

2010 (7 papers)

  1. Effect of Alzheimer disease genetic risk disclosure on dietary supplement use.
    Vernarelli JA, Roberts JS, Hiraki S, et al. · Am J Clin Nutr · 2010 · Background
    PubMed: PMID 20219963 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  2. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab.
    Li Z, Arijs I, De Hertogh G, et al. · Inflamm Bowel Dis · 2010 · Background
    PubMed: PMID 20196149 · NCT03885713 (BioIBD) · Crohn Disease
  3. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis.
    Li NC, Lee A, Whitmer RA, et al. · BMJ · 2010 · Background
    PubMed: PMID 20068258 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease
  4. Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life.
    Ho SG, Yeung CK, Chan HH, et al. · Clin Exp Dermatol · 2010 · Background
    PubMed: PMID 19925489 · NCT02330380 · Psoriasis
  5. Infliximab, azathioprine, or combination therapy for Crohn's disease.
    Colombel JF, Sandborn WJ, Reinisch W, et al. · N Engl J Med · 2010 · Background
    PubMed: PMID 20393175 · NCT03885713 (BioIBD) · Crohn Disease
  6. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.
    Atteno M, Peluso R, Costa L, et al. · Clin Rheumatol · 2010 · Background
    PubMed: PMID 20066450 · NCT02330380 · Psoriasis
  7. A cost-effectiveness comparison of liquor carbonis distillate solution and calcipotriol cream in the treatment of moderate chronic plaque psoriasis.
    Alora-Palli MB, Brouda I, Green B, et al. · Arch Dermatol · 2010 · Background
    PubMed: PMID 20713833 · NCT02330380 · Psoriasis

2009 (4 papers)

  1. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study).
    Solberg IC, Lygren I, Jahnsen J, et al. · Scand J Gastroenterol · 2009 · Background
    PubMed: PMID 19101844 · NCT05386290 · Crohn Disease
  2. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis.
    Olsen T, Goll R, Cui G, et al. · Cytokine · 2009 · Background
    PubMed: PMID 19286392 · NCT03885713 (BioIBD) · Crohn Disease
  3. Differential proteomic analysis of HT29 Cl.16E and intestinal epithelial cells by LC ESI/QTOF mass spectrometry.
    Nanni P, Mezzanotte L, Roda G, et al. · J Proteomics · 2009 · Background
    PubMed: PMID 19168159 · NCT03885713 (BioIBD) · Crohn Disease
  4. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.
    Arijs I, Li K, Toedter G, et al. · Gut · 2009 · Background
    PubMed: PMID 19700435 · NCT03885713 (BioIBD) · Crohn Disease

2008 (11 papers)

  1. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
    Sandborn WJ, Feagan BG, Fedorak RN, et al. · Gastroenterology · 2008 · Derived
    PubMed: PMID 18706417 · NCT00265122 · Crohn Disease
  2. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
    Papp KA, Langley RG, Lebwohl M, et al. · Lancet · 2008 · Derived
    PubMed: PMID 18486740 · NCT00307437 · Psoriasis
  3. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
    Leonardi CL, Kimball AB, Papp KA, et al. · Lancet · 2008 · Derived
    PubMed: PMID 18486739 · NCT00267969 (PHOENIX1) · Psoriasis
  4. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).
    Saurat JH, Stingl G, Dubertret L, et al. · Br J Dermatol · 2008 · Background
    PubMed: PMID 18047523 · NCT02330380 · Psoriasis
  5. Current directions in IBD therapy: what goals are feasible with biological modifiers?
    Sandborn WJ · Gastroenterology · 2008 · Background
    PubMed: PMID 18848556 · NCT05186623 · Colitis, Ulcerative
  6. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
    Reich K, Sinclair R, Roberts G, et al. · Curr Med Res Opin · 2008 · Background
    PubMed: PMID 18355421 · NCT02330380 · Psoriasis
  7. Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis.
    Nanni P, Parisi D, Roda G, et al. · Rapid Commun Mass Spectrom · 2008 · Background
    PubMed: PMID 18022963 · NCT03885713 (BioIBD) · Crohn Disease
  8. Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study.
    Meuwis MA, Fillet M, Lutteri L, et al. · Clin Biochem · 2008 · Background
    PubMed: PMID 18489908 · NCT03885713 (BioIBD) · Crohn Disease
  9. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category.
    Luger D, Silver PB, Tang J, et al. · J Exp Med · 2008 · Background
    PubMed: PMID 18391061 · NCT01647152 · Uveitis
  10. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial.
    Flytström I, Stenberg B, Svensson A, et al. · Br J Dermatol · 2008 · Background
    PubMed: PMID 17986302 · NCT02330380 · Psoriasis
  11. Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study.
    Chao S, Roberts JS, Marteau TM, et al. · Alzheimer Dis Assoc Disord · 2008 · Background
    PubMed: PMID 18317253 · NCT02835716 (PCD=OOALZ) · Alzheimer Disease

2007 (7 papers)

  1. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
    Krueger GG, Langley RG, Leonardi C, et al. · N Engl J Med · 2007 · Derived
    PubMed: PMID 17287478 · NCT00320216 · Psoriasis
  2. Unravelling the pathogenesis of inflammatory bowel disease.
    Xavier RJ, Podolsky DK · Nature · 2007 · Background
    PubMed: PMID 17653185 · NCT05186623 · Colitis, Ulcerative
  3. Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease.
    Shkoda A, Werner T, Daniel H, et al. · J Proteome Res · 2007 · Background
    PubMed: PMID 17330946 · NCT03885713 (BioIBD) · Crohn Disease
  4. Infliximab in fistulizing Crohn's disease.
    Osterman MT, Lichtenstein GR · Gastroenterol Clin North Am · 2007 · Background
    PubMed: PMID 17129814 · NCT07495644 · Crohn Disease
  5. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
    Kamm MA, Sandborn WJ, Gassull M, et al. · Gastroenterology · 2007 · Background
    PubMed: PMID 17241860 · NCT03885713 (BioIBD) · Crohn Disease
  6. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.
    D'Haens G, Sandborn WJ, Feagan BG, et al. · Gastroenterology · 2007 · Background
    PubMed: PMID 17258735 · NCT03885713 (BioIBD) · Crohn Disease
  7. Trends in hospitalization rates for inflammatory bowel disease in the United States.
    Bewtra M, Su C, Lewis JD, et al. · Clin Gastroenterol Hepatol · 2007 · Background
    PubMed: PMID 17382602 · NCT03885713 (BioIBD) · Crohn Disease

2006 (3 papers)

  1. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
    Van Assche G, Sandborn WJ, Feagan BG, et al. · Gut · 2006 · Background
    PubMed: PMID 16603634 · NCT03885713 (BioIBD) · Crohn Disease
  2. Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency.
    Mannon PJ, Fuss IJ, Dill S, et al. · Gastroenterology · 2006 · Background
    PubMed: PMID 16952544 · NCT02199496 · Diarrhea
  3. Comparative proteomic studies on the pathogenesis of human ulcerative colitis.
    Hsieh SY, Shih TC, Yeh CY, et al. · Proteomics · 2006 · Background
    PubMed: PMID 16947118 · NCT03885713 (BioIBD) · Crohn Disease

2005 (2 papers)

  1. Infliximab for induction and maintenance therapy for ulcerative colitis.
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. · N Engl J Med · 2005 · Background
    PubMed: PMID 16339095 · NCT05186623 · Colitis, Ulcerative
  2. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD.
    Daperno M, D'Haens G, Van Assche G, et al. · Gastrointest Endosc · 2005 · Background
    PubMed: PMID 15472670 · NCT03885713 (BioIBD) · Crohn Disease

2004 (3 papers)

  1. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences.
    Loftus EV · Gastroenterology · 2004 · Background
    PubMed: PMID 15168363 · NCT03885713 (BioIBD) · Crohn Disease
  2. Proteomic analysis of the intestinal epithelial cell response to enteropathogenic Escherichia coli.
    Hardwidge PR, Rodriguez-Escudero I, Goode D, et al. · J Biol Chem · 2004 · Background
    PubMed: PMID 14988394 · NCT03885713 (BioIBD) · Crohn Disease
  3. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study.
    Gritz DC, Wong IG · Ophthalmology · 2004 · Background
    PubMed: PMID 15019324 · NCT01647152 · Uveitis

2003 (1 paper)

  1. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.
    Heydendael VM, Spuls PI, Opmeer BC, et al. · N Engl J Med · 2003 · Background
    PubMed: PMID 12917302 · NCT02330380 · Psoriasis

2002 (2 papers)

  1. Immunosuppression in uveitis.
    Djalilian AR, Nussenblatt RB · Ophthalmol Clin North Am · 2002 · Background
    PubMed: PMID 12434489 · NCT01647152 · Uveitis
  2. Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: implications for inflammatory bowel diseases.
    Barceló-Batllori S, André M, Servis C, et al. · Proteomics · 2002 · Background
    PubMed: PMID 11987129 · NCT03885713 (BioIBD) · Crohn Disease

1999 (1 paper)

  1. Common variable immunodeficiency: clinical and immunological features of 248 patients.
    Cunningham-Rundles C, Bodian C · Clin Immunol · 1999 · Background
    PubMed: PMID 10413651 · NCT02199496 · Diarrhea

1978 (1 paper)

  1. Control of immunoglobulin secretion in the murine plasmacytoma line MOPC 315.
    Sonenshein GE, Siekevitz M, Siebert GR, et al. · J Exp Med · 1978 · Background
    PubMed: PMID 97359 · NCT02684357 · Psoriasis

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).